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Abstract 
 
Atherosclerosis is a chronic inflammatory disease leading to the formation of vascular 
plaques within the major arteries. Vascular plaques consist of a collection of 
inflammatory cells, extracellular matrix and fibrous material. Advanced plaques are 
characterised by the formation of necrotic zones often containing free lipid deposits high 
in cholesterol esters. Though considerable work has been published on the contents of 
these atherosclerotic plaques very little is known about how the composition varies along 
the length of the plaque. Nor is it known whether the pterin, 7,8-dihydroneopterin, is 
released by activated macrophages at levels where it can alter the plaque development 
through it’s antioxidant activity.  
 
Atherosclerotic plaques were removed from patients carotid and femoral arteries during 
endarectomy surgery and sliced into 3-5 cm sections along the length of the plaque. For 
each segment the concentrations of neopterin, 7,8-dihydroneopterin, α-tocopherol, 
TBARS, DOPA, dityrosine, the protein carbonyls α-Aminoadipic semialdehyde (AAS) 
and γ-glutamic semialdehyde (GGS), 7-ketocholesterol, and cholesterol was measured. 
Plasma samples were taken from around the sites of coronary plaques during angioplasty 
procedures and the concentrations of neopterin and 7,8-dihydroneopterin was measured.  
 
The oxidant, antioxidant and inflammatory markers analysed in the atherosclerotic 
plaques showed many strong positive correlations between pairs of markers. The 
strongest was between α-tocopherol and cholesterol with significant correlations in the 
majority of plaques analysed. Combined plaque data analysed by dividing the segments 
up into three zones, pre-bifurcation, bifurcation and post-bifurcation showed that the 
formation of both protein and lipid oxidation markers were significantly high in the pre-
bifurcation zones while alpha tocopherol was highest in the post-bifurcation zone but 
failed to reach significants. The pre-bifurcation zone is thought to be associated with a 
low shear stress level in the plaque and therefore where the oxidants localise. Neopterin 
levels tended also to be high in the pre-bifurcation zones but failed to reach significants. 
Pterin levels of as high as 2 μM were recorded suggesting in some regions 7,8-
dihydroneopterin levels may reach antioxidant levels. The high variability could suggest 
that pterin and therefore inflammation within the plaque is a very dynamic and variable 
 ix
process. Overall the data shows that each individual plaque’s composition was relatively 
unique and variable over the length of the plaque.   
 
The plasma samples taken from around coronary plaques showed 7,8-dihydroneopterin 
levels were on average elevated 3 fold compared to controls with neopterin levels only 
elevated 2 fold. This suggests 7,8-dihydroneopterin oxidation was not greatly elevated in 
these patients and the inflammation was an ongoing process. 
 
The study shows that 7,8-dihydroneopterin and neopterin production and release is a 
dynamic process in vascular disease patients. The level of variability though between 
patients prevents the importance of pterin production on the disease progression to be 
determined with the current data set.  
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Introduction 1
Introduction 
 
1.1   Atherosclerosis 
Atherosclerosis is a progressive inflammatory disease and the leading cause of death in 
the developed world. Atherosclerosis is characterised by the accumulation of lipids 
within the walls of medium to large sized arteries, leading to the formation of 
atherosclerotic plaques. Advanced atherosclerotic plaques often have narrowing of the 
arterial lumen, which restricts and eventually blocks blood flow through the artery 
resulting in clinical complications. More severe clinical events such as myocardial 
infraction and stroke are often preceded by plaque rupture, an event where the plaque 
contents spills into the blood flow forming a blood clot (thrombus). This causes a sudden 
stoppage in the blood flow through the artery. In New Zealand cardiovascular disease 
accounted for 40% of all deaths in 2000 (Hay, 2004). It is also estimated to account for 
11% of non fatal disease burden and 24% of disability (Ministry of Health, 2001). The 
main risk factors leading to advanced atherosclerotic plaque formation are elevated 
plasma cholesterol levels, hypertension, diabetes and smoking (Chatzizisis et al., 2007; 
Falk, 2006; Scott, 2004). Atherosclerosis is a slow and complex disease which progresses 
over decades, often without symptoms until later in life. This disease, although widely 
studied, is still poorly understood with debate on the actual mechanism for plaque 
formation and development. Understanding the processes involved in plaque initiation, 
progression and the resulting clinical events could greatly help toward controlling and 
treating this disease. 
 
1.1.1   Plaque Development and Inflammation 
Arteries consist of three layers, the intima, the media and the adventitia (Figure 1.1). 
Atherosclerotic plaques form within the intimal layer of the artery in response to a build 
up of lipoprotein particles (Lusis, 2000). The intimal layer is lined with endothelial cells 
that allow the low density lipoproteins (LDL) to migrate through and gather within the 
intima. Endothelial cells act to ensure the bodies homeostasis, but they also reside in a 
highly vulnerable position. Changes in the blood flow can gradually induce endothelial 
cell dysfunction which can increase their permeability, as well as the surface expression 
of cell adhesion molecules and chemokines (Poli et al., 2009). An early step in the 
Introduction 2
formation of plaques is the recruitment and adhesion of inflammatory cells to the artery 
endothelium. Inflammation plays a key role in the development of atherosclerosis with 
local inflammation initiating in the formation of plaques (Lind, 2003). This causes the 
migration and presence of inflammatory cells into the intima, such as monocytes and T 
cells (Chatzizisis et al., 2007). Monocytes are able to enter the intimal space by adhesion 
to the vascular cell adhesion molecule-1 (VCAM-1). 
 
 
Figure 1.1 Defined Layers of the Arterial Vessel Wall 
A single layer of endothelial cells provides the barrier between the arterial tissue and the 
flowing blood. The intima, site of plaque formation, and the media both consist of layers 
of smooth muscle cells with the adventitia forming the outer layer of the artery. Adapted 
from Libby 2002. 
 
VCAM-1 is not expressed on healthy endothelial cells, but its up-regulation is induced by 
the accumulation of LDL particles and mediated by nuclear factor-κβ (NF-κβ) and pro-
inflammatory cytokines which initiate the inflammatory response. (Hansson & Libby, 
2006; Libby, 2002; Ross, 1999). Once bound to VCAM-1 monocytes require a 
chemoattractant gradient provided by the monocytes chemoattractant protein-1 (MCP-1) 
to migrate through the endothelial cells (Libby, 2004). MCP-1 is an inflammatory 
cytokine that appears to be one of the key biochemical mediators in chronic 
inflammatory reactions that underlie and promote the progression of atherosclerosis (Poli 
et al., 2009). Within the intimal space the monocytes differentiate into macrophages 
under the influence of macrophage colony-stimulating factor (M-CSF) (Hansson & 
Libby, 2006). LDL in the intima is oxidised by reactive oxygen species (ROS) to form 
oxidised LDL (oxLDL) through mechanisms which are poorly understood (Falk, 2006), 
but during the oxidation there is a modification to the apolipoprotein B-100 which 
renders the oxLDL susceptible to macrophage uptake (Stocker & Keaney, 2004). The 
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oxLDL is taken into the macrophage in a rapid and unregulated manner through the 
scavenger receptors CD36 and scavenger receptor-A (SC-A), leading to lipid laden 
macrophages known as foam cells. OxLDL is toxic to cells, and causes the death of the 
foam cells via necrosis. Over time these dead foam cells accumulate to form the lipid rich 
necrotic core. 
 
 
Figure 1.2 Process Involved in the Formation and Progression of Atherosclerotic 
Plaques 
LDL and monocytes from the blood channel migrate into the intimal layer of the artery. 
The LDL becomes oxidised and the monocytes differentiate into macrophages. The 
macrophages accumulate cholesterol by the uncontrollable uptake of oxLDL leading to 
the formation of foam cells. Continuation of this process leads to the formation of the 
complex plaque. Symptoms can occur through occlusion of blood flow and/or plaque 
rupture. Adapted from Libby 2002b. 
 
During this process of LDL oxidation and plaque development many biochemical 
markers such as oxidised lipids and proteins, anitoxidants and inflammatory markers are 
formed and become incorporated into the plaque. ROS within the plaque oxidises the 
amino acids on the apoB protein of LDL to form the protein carbonyls α-Aminoadipic 
semialdehyde (AAS) and γ-glutamic semialdehyde (GGS), and the protein oxidation 
products DOPA and dityrosine. The ROS are also able to oxidise the PUFAs and 
cholesterol within the LDL in macrophage foam cells to produce TBARS and 7-
ketocholesterol. Inflammation occurring within the plaque activates macrophages 
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allowing them to produce 7,8-dihydroneopterin, which can be further oxidised to form 
neopterin. The concentration of these markers can be quantified along the length of 
advanced atherosclerotic plaques to help understand where in the plaque the majority of 
the oxidation and inflammation may be occurring.  
 
1.1.2 Plaque Progression, From Early to Advanced Lesions 
Atherosclerotic plaques are categorised into six levels of severity, ranging from the very 
early stage of lesion formation, type I, through to the advanced clinically complicated 
lesions, type VI. The lesions increase in size and complexity as the lipoproteins 
accumulate (Figure 1.3). Type I lesions (initial lesions) are characterised by the adaptive 
thickening of the intima and the first lipid deposits. The lipids are contained within small 
isolated groups of macrophages that form the first foam cells. Initial lesions are often 
found in children and the majority are not visible by the unaided eye (Stary et al., 1994). 
Type II lesions (fatty streaks) may be seen as yellow coloured streaks on the intimal 
surface of an artery, although they are not always clearly visible. Intimal smooth muscle 
cells can contain lipid droplets but the majority of the lipids are found within macrophage 
foam cells which begin to form into adjacent layers (Stary et al., 1994). Type II lesions 
can be sub-grouped into type IIa and type IIb. Type IIa lesions are referred to as ‘advance 
lesion-prone’, they are found in locations with mechanical forces, such as low shear 
stress, often at branch points and major curvature in arteries (Stary et al., 1994; 
Gimborne, 1999). Low endothelial shear stress (ESS) increases the susceptibility of a 
lesion to progress further. Type IIb lesions are known as ‘advanced lesion-resistant’, they 
are found in areas where the intima is thin and contains few smooth muscle cells. Type 
IIb lesions either do not progress, progress slowly or progress only in people with very 
high plasma cholesterol levels (Stary et al., 1994). 
Type III lesions (intermediate lesions) show the initiation of the necrotic lipid core. As 
the macrophage foam cells undergo necrosis the lipids begin to form small extracellular 
pools within the intima (Stary et al., 1994; Stocker & Keaney, 2004).  
In type IV lesions (atheromas) the extracellular lipids form into a dense core in an 
extensive but well defined region of the intima. Some smooth muscles may become 
calcified and there is generally minimal narrowing of the lumen (Stary et al., 1995; 
Stocker & Keaney, 2004).  
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Figure 1.3 Varying Stages of Atherosclerosis 
The progression of atherosclerosis is depicted from the earliest stages (top left) to the 
most advanced (bottom right) culminating in plaque rupture and associated thrombosis. 
Adapted from Stary 2004. 
 
Type V lesions (fibroatheroma) have thick layers of fibrous connective tissue forming 
between the lipid core and the endothelial cells, and is what is known as the fibrous cap 
(Stary et al., 1995; Stocker & Keaney, 2004). As the lesion grows one of two things 
happen, the plaque can either undergo constrictive remodelling causing the lumen to 
become narrower affecting the blood flow through the artery, or the plaque could 
undergo expansive remodelling which causes the diameter of the artery to enlarge 
leaving the luminal space relatively unaffected. Expansive remodelling often results in an 
unstable plaque as the larger luminal circumference creates greater stress on the fibrous 
cap therefore increasing the likelihood that the cap will rupture (Shan, 2003; Libby, 
2004; Falk, 2006). 
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Type VI (complicated lesions) are defined by disruptions to the lesion surface in the form 
of thrombus formation, haemorrhage or hematoma, all of which can cause the plaque to 
become even more prone to rupture (Stary et al., 1995; Stocker & Keaney, 2004). 
 
The fibrous cap provides protection and stability to the plaque by encasing the lipid core 
and separating its pro-coagulant factors from the blood flow (Shan, 2003; Libby, 2004). 
As the plaques lipid core grows the cap begins to thin, especially at the edges, known as 
shoulder regions. The cap can also be broken down by matrix metalloproteinases (MMP) 
expressed in the plaque by macrophage foam cells that degrade to caps collagen (Shan, 
2003; Jang et al., 1993). Thin, weakened caps are prone to rupture, an event that allows 
the lipid core to come in contact with the blood flow resulting in thrombus formation. A 
thrombotic event causing the blockage of blood flow through the artery is responsible for 
the majority of clinical events associated with atherosclerosis (Stary et al., 1995). A 
blockage in a coronary artery can cause a myocardial infarction or angina, a blockage in 
a carotid artery results in stoke or transient ischemic attack, and when the femoral arteries 
become blocked tissue death and gangrene can occur in the legs. 
 
1.1.3 Endothelial Shear Stress (ESS) and Localisation of Plaques 
Atherosclerotic plaques commonly form in specific areas in the arteries, such as branch 
points and areas of major curvature (Gimborne, 1999). This is due to these regions being 
under local hemodynamic forces, including blood flow-generated endothelial shear stress 
(ESS) (Chatzizisis et al., 2007; Gotlieb, 2005). ESS is generated thought the friction of 
the flowing blood on the surface of endothelial cells in the arterial wall (Chatzizisis et al., 
2007). As the blood flows into the artery bifurcations the flow is disturbed, resulting in 
low and oscillatory ESS (Figure 1.4) (Chatzizisis et al., 2007; Ding et al., 2001). Low 
ESS occurs in regions of unidirectional flow and is often in the inner areas of curvatures 
and up stream of stenosis (Chatzizisis et al., 2007; Papaioannou et al., 2006). Oscillatory 
ESS causes bidirectional stress on the artery, this generally occurs at branch points and 
downstream of bifurcations (Chatzizisis et al., 2007). 
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Figure 1.4 Example of Low and Oscillatory Shear Stress. 
This shows the disruption to the blood at a branch point and bifurcation area resulting in 
endothelial shear stress. Adapted from Chatzizisis et al., 2007. 
 
Normal ESS promotes endothelial cell stability, it has a positive affect on the cells 
survival and it can limit the expression of VCAM-1 by inhibiting NF-κβ activation 
(Libby, 2002). On the other hand, low ESS can promote endothelial dysfunction, increase 
monocyte binding and expression of adhesion molecules through inducing NF-κβ 
activation. Low ESS can also promote vascular remodelling and increase the 
permeability of the endothelial surface to LDL (Chatzizisis et al., 2007; Honda et al., 
2001; Papaioannou et al., 2006). The low ESS in bifurcation regions allows a prolonged 
resident time of LDL and leucocytes on the arterial wall surface, therefore favouring their 
attachment and infiltration into the intima (Gimborne, 1999). Both low and oscillatory 
ESS have been identified to contribute to the initiation and progression of atherogenesis 
(Chatzizisis et al., 2007; Gimborne, 1999). 
 
1.2 Free Radicals 
Free radicals are very reactive molecules that contain an unpaired electron. They are 
produced continuously in cells, generally as by products of cellular metabolism (Dalle-
Donne et al., 2003; de Zwart et al., 1998; Gebicki and Gebicki, 1999). The most 
important reactions of free radicals in aerobic cells involve molecular oxygen and its 
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radical derivatives to form reactive oxygen species (ROS) (de Zwart et al., 1998). Small 
amounts of ROS are a cellular requirement as they are involved in cell signalling 
pathways and defence mechanisms. Although they do not inevitably result in biological 
damage, an over production of ROS is potentially harmful (Dalle-Donne et al, 2003; 
Gebicki and Gebicki, 1999). Since ROS has the potential to induce significant biological 
damage, cells have many antioxidant systems for scavenging and eliminating them. 
Oxidative stress and cellular damage only occur when the normal homeostasis of the cell 
is upset and the rate of formation of ROS exceeds the capacity of the antioxidant defence 
system (Dalle-Donne et al., 2003; Cipollone et al., 2007). ROS can damage all types of 
biomolecules such as, nucleic acids, lipids and proteins. This can lead to cell death and 
tissue injury (Dalle-Donne et al., 2003; de Zwart et al., 1998; Levine, 2002). These 
highly reactive chemical species are not only important in the aging process, but they are 
also involved in various clinical disorders including atherosclerosis (de Zwart et al., 
1998). The direct reaction of a short lived ROS with a biomolecule usually results in its 
oxidation and this product could be a new reactive molecule capable of oxidising or 
altering other biomolecules (Gebicki and Gebicki, 1999). ROS and/or their modified 
target biomolecules (i.e. oxLDL) can serve as second messengers and transmit 
extracellular signals to elevate the expression of atherogenic gene products, such as 
adhesion molecules and other vascular inflammatory gene products. The induced 
expression of these gene products promotes the infiltration of monocytes into the vessel 
wall and the release of additional pro-inflammatory signals which can effect 
inflammatory cells adhesion, migration, proliferation and differentiation (Cipollone et al., 
2007; Patel et al., 2000). Both the primary and secondary products of radical damage can 
be used as biomarkers to monitor various disease states. Oxidised lipids and proteins are 
easily detected and quantified to access the level of oxidative damage occurring in 
biological samples. 
 
1.2.1 Oxidation of Low Density Lipoprotein 
LDL is the main carrier of free and esterified cholesterol in the blood. It is made up of 
42% cholesterol esters, 22% phospholipids, 22% from the one apoB protein, 10% free 
cholesterol and 6% triglycerides (Esterbauer et al.1992). It is well established that one of 
the risk factors for atherosclerosis is high plasma LDL (Steinberg et al 1989), as LDL is 
oxidised and retained within the artery wall. This oxidation occurs within the arterial wall 
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most likely because this is an environment where the antioxidants can become depleted 
and the lipoproteins are exposed to oxidative stress (Berliner & Heinecke, 1996). Once 
oxidised the LDL contributes to atherogenesis by recruiting monocytes to the artery wall, 
activating the cell adhesion molecule VCAM-1 and stimulating the release of the pro-
inflammatory cytokines MCP-1 and MCSF (Berliner & Heinecke, 1996; Steinberg, 
1997). The oxidation of LDL produces the oxidation markers we have quantified in this 
study. The apoB protein on LDL contains 4536 amino acids (Steinberg, 1997), from 
which the oxidation of tyrosine can form DOPA and dityrosine and the oxidation of 
lysine, arginine and proline and form the protein carbonyl products α-Aminoadipic 
semialdehyde (AAS) and γ-glutamic semialdehyde (GGS). The PUFAs within the LDL 
are subject to free radical oxidation generating TBARS, while the cholesterol in the LDL, 
both free and esterified, is converted to 7-ketocholesterol via direct oxidative attack 
(Steinberg, 1997). 
 
1.2.2 Lipid Oxidation 
Lipid oxidation is a process occurring when the double bond in polyunsaturated fatty 
acids (PUFAs) is attacked by free radicals. This initiation reaction proceeds when a 
radical (R•) removes a hydrogen atom from the PUFA (LH), generating a fatty acid 
radical (L•) (Reaction 1). The fatty acid radical can then rapidly react with oxygen (O2) to 
form a fatty acid peroxyl radical (LOO•) (Reaction 2). Adjacent unsaturated fatty acids 
(L’H) will be attracted by LOO• promoting further oxidative damage to lipids. Oxidation 
is therefore a self-propagating chain reaction that can lead to the formation of lipid 
hydroperoxides (LOOH) (Reaction 3). The termination of this reaction occurs when fatty 
acid peroxyl radicals (LOO•) react with each other or endogensis antioxidants to produce 
non-radical products (NRP) (Reaction 4) (Cheeseman and Slater, 1993). 
 
(1) LH + R• → L• + RH 
(2) L• + O2 → LOO• 
(3) LOO• + L’H → LOOH + L• 
(4) LOO• + LOO• → NR 
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Lipid oxidation occurs in three distinct steps. A lag phase with little or no oxidation 
where the initiating or propagating radicals are removed by antioxidants, a propagation 
phase of increasing lipid oxidation and a final phase with a decrease in lipid oxidation, 
caused by more products being degraded than formed (Esterbauer et al; 1992; Halliwell 
and Gutteridge, 1999). Accumulation of oxidised lipid has been found in human 
atherosclerotic lesions from the earliest to the most advanced stages of lesion 
development, providing evidence of ongoing lipid oxidation within atherosclerotic 
lesions (Berliner, 2002; Jachec et al., 2003; Smith et al., 1992). The most widely used 
index of lipid peroxidation is by MDA formation, measured by the TBARS assay. 
 
1.2.3 7-Ketocholesterol 
 Oxysterols, in particular 7-ketocholesterol (7-KC), are also a good marker of lipid 
oxidation (de Zwart et al., 1998; Fu et al., 1998). This is because during the course of 
LDL oxidation around 50% of its cholesterol is converted into oxysterols (Brown & 
Jessup, 2009). 7-KC is formed by the direct radical attack on cholesterol by ROS at the 
C-7 position (Brown & Jessup, 2009; Lyons and Brown, 1999). 7-Ketocholesterol is the 
second most abundant oxysterol found in human atherosclerotic plaques, after 27-
hydroxycholesterol, and 80-95% of it is found as esters (Brown & Jessup, 2009; Lyons 
and Brown, 1999). Esterification of excess cholesterol in cells is mediated by acyl-CoA 
cholesterol acyl transferase (ACAT), this is a normal cellular mechanism for limiting the 
levels of free (unesterified) cholesterol in cell membranes in order to maintain normal 
membrane structure, ACAT also esterifies many oxidised forms of cholesterol (Brown & 
Jessup, 2009). It has also been suggested that some of the 7-KC present in atherosclerotic 
tissue and circulating plasma may come from dietary sources, as 7-KC is the major 
oxysterol found in cholesterol-rich foods such as meat, eggs and dairy products (Brown 
& Jessup, 2009; Lyons and Brown, 1999). 
 
1.2.4 Protein Oxidation. 
Proteins are major targets for free radical attack due to their abundance in cells (Davies et 
al., 1999; Gebicki, 1997). Free radicals are able to alter the protein structure by 
modification to the amino acid side chains, cleavage of the peptide backbone and DNA 
cross-linking (Akagawa et al., 2006; Gebicki and Gebicki, 1999). The oxidation of 
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proteins by free radicals and ROS can generate a range of stable and reactive products. 
The oxidation of aromatic side chains on tyrosine, can form DOPA and dityrosine. While 
a direct oxidative attack on lysine, arginine and proline can lead to the formation of 
protein carbonyl derivatives (Akagawa et al., 2006; Davies et al., 1999; Dean et al., 1997; 
Fu et al., 1998; Simpson et al., 1992). A large body of evidence suggests that protein 
oxidation plays a major role in a number of human diseases and conditions such as aging, 
Alzheimer’s disease, diabetes and atherosclerosis (Akagawa et al., 2006; Dean et al., 
1997, Fu et al., 1998). 
 
1.2.5 Protein carbonyls 
ROS mediated oxidative modification to amino acid side chains can produce carbonyl 
derivatives. Protein carbonyls are relatively stable and unreactive making them a useful 
marker of oxidation, they can be used to measure and quantify the oxidative damage to 
proteins in biological samples (Dalle-Donne et al., 2003; Davies et al., 1999). It has been 
confirmed that carbonyl derivatives can accumulate on tissue proteins during ageing, 
with the carbonyl content increasing dramatically after the sixth decade of life reaching a 
level where on average one out of every three protein molecules carries a modification 
(Akagawa et al., 2006; Levine, 2002). This increase in protein carbonyl content in tissues 
is associated with a number of pathological disorders including rheumatoid arthritis, 
Alzheimer’s disease, respiratory distress syndrome, Parkinson’s disease and 
atherosclerosis (de Zwart et al., 1998). α-Aminoadipic semialdehyde (AAS) and γ-
glutamic semialdehyde (GGS) are considered to be the main carbonyl products produced 
from metal-catalyzed oxidized (MCO) systems and are used as specific biomarkers of 
oxidative damage.  AAS derives from the oxidation of lysine residues, while GGS 
originates from the oxidation of arginine and proline (Akagawa et al., 2006; Armenteros 
et al., 2009: Miyata et al., 1998). Both AAS and GGS can be generated by oxidative 
stress in vivo, suggesting that their measurements can provide useful information on the 
contribution of oxidative stress on various diseases and ageing (Akagawa et al., 2006). 
 
1.2.6 DOPA and Dityrosine 
Protein bound 3,4-dihydroxyphenylalanine (PB-DOPA) is a major reducing species 
produced by hydroxyl radical attack on tyrosine residues (Dean et al., 1993). Tyrosine 
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can be oxidised to form mainly DOPA with some dityrosine (Davies et al., 1999; Linton 
et al., 2001). PB-DOPA is a relatively stable species and therefore it has the ability to 
diffuse to other sites, allowing it to cause damage to other proteins (Rodgers and Dean, 
2000). It has the potential to initiate further oxidative reactions by binding and reducing 
transition metals, such as iron and copper. This can mediate further redox processes 
which may inflict secondary damage to other biomolecules (Fu et al., 1998; Rodgers and 
Dean, 2000). Because of this it has been hypothesised that DOPA is involved in the 
progression of plaque development (Rodgers and Dean, 2000).  
Dityrosine, a very stable compound, is formed when two tyrosyl radicals react together. 
The long lived tyrosyl radicals can be produced from the one-electron oxidation of L-
tyrosine in the presence of myeloperoxidase (de Zwart et al., 1998; Heinecke et al., 
1993). Due to the stability and the fluorescence of both PB-DOPA and dityrosine, they 
make useful markers to measure protein oxidation in tissues (Fu et al., 1998). HPLC 
analysis has shown that radical-damaged proteins contain significant amounts of PB-
DOPA (Gieseg et al., 1993). The levels of dityrosine in atherosclerotic regions of human 
aorta have been shown to be clearly increased, with the highest levels reported in early 
fatty streaks, However the actual ratio is only one dityrosine residue to every 3300 
tyrosine residues (Levine, 2002). 
 
1.3 Antioxidants in Biological Systems 
Antioxidants are capable of removing and converting free radicals and/or oxidants into a 
less reactive state. Antioxidant activity can occur via enzymatic removal, for example 
using the enzyme superoxide dismutase to remove superoxide, or through compounds 
like α-tocopherol and ascorbic acid which scavenge free radicals (Halliwell and 
Gutteridge, 1999). Plasma contains a number of antioxidants, making blood a highly 
protected environment against oxidative stress. Many antioxidants have been identified 
within atherosclerotic plaques, these include α-tocopherol, ascorbic acid, ubiquinol-10, 
uric acid, glutathione peroxidise, glutathione reductase and the three isoforms of 
superoxide dismutase (Stocker and Keaney, 2004). Despite this protection oxidative 
damage still occurs within plaques. 
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1.3.1 Antioxidants, α-Tocopherol and Ascorbic Acid 
α-Tocopherol and ascorbic acid have been suggested to limit oxidative damage and 
therefore lower the risk of certain diseases in humans (Villacorta et al., 2007). α-
Tocopherol is a major lipid soluble chain-breaking antioxidant and the most biologically 
active form of vitamin E (Lui et al., 2004; Suarna et al., 2006). Located in the lipid 
bilayer α-tocopherol can protect both the membrane and membrane-bound enzymes from 
oxidative stress (Martin et al., 1996). It is also capable of protecting LDL against lipid 
peroxidation by directly scavenging free radicals and rapidly reacting with the lipid 
peroxyl radical (LOO•) to form the less reactive α-tocopherol racial (α-Toc•) (Reaction 5) 
(Kontush et al., 1996; Thomas and Stocker, 2000). α-Tocopherol (α-TocH) can also 
directly react with the initiating radical to prevent LOO• formation. The α-Toc• radical 
can then be eliminated by a radical-radical reaction with another LOO• generating a non 
radical product (Reaction 6) (Bowry and Stocker, 1993; Thomas and Stocker, 2000). 
Both α-TocH and the α-Toc• have the ability to scavenge radicals, therefore each 
molecule of α-TocH has the potential to terminate two radicals (Bowry and Stocker, 
1993; Thomas and Stocker, 2000).  At high radical fluxes the concentration of LOO• is 
enough for reaction 6 to predominate, resulting in both prevention of lipid peroxidation 
and rapid consumption of the α-Toc• radical (Bowry and Stocker, 1993). Under a low 
radical flux the reduced concentrations of LOO• makes reaction 6 become infrequent and 
this allows α-tocopherol to switch into a pro-oxidant state (Reaction 7) (Bowry and 
Stocker, 1993). 
α-Tocopherol is not only an antioxidant, it can also act as a pro-oxidant. One of these 
pro-oxidant abilities is to reduce free Cu2+ to Cu+ potentially contributing to a pool of 
redox active metals within the system (Yoshida et al., 1994). 
 
(5)  α-TocH + LOO•  → α-Toc•  + LOOH 
(6)  α-Toc• + LOO•  → LOOH + non radical product 
(7)  α-Toc• + LH → L•  +  α-TocH 
Ascorbic acid is a water soluble antioxidant which predominantly occurs in its redox 
active state (Halliwell and Gutteridge, 1999; Suarna et al., 1995). It is both an anti- and 
pro-oxidant, able to reduce metals, hydroxyl radicals and superoxide. This antioxidant is 
recycled via the disproportional reaction between two ascorbyl radicals (Halliwell and 
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Gutteridge, 1999). Ascorbic acid has been localised within plaques at concentrations 
higher than that detected within normal arterial tissue (Suarna et al., 1995). 
 
1.3.2 Neopterin and 7,8-Dihydroneopterin 
7,8-Dihydroneopterin (7,8-NP) and its oxidation product neopterin are produced in 
response to immune cell activation. This makes these both excellent inflammatory 
markers within the atherosclerotic plaque. When inflammation occurs in the arterial 
intima activated T cells release γ-interferon, this up-regulates Guanosine Triphosphate 
(GTP)-cyclohdrolase which converts GTP into dihydroneopterin inside activated 
macrophages. Intracellular phosphotates cleaves the triphosphate, this leaves 7,8-NP to 
diffuse out of the macrophages and into intracellular spaces and plasma (Figure 1.5) 
(Gieseg et al., 2008; Hamerlinck, 1999; Hoffmann et al., 2003). 7,8-NP can then be 
oxidised to neopterin in the presence of hypochlorite (HOCl) (Widner et al., 2000). 
 
Figure 1.5 Overview of the Synthesis of 7,8-Dihyreonoepterin and Neopterin 
γ-Interferon stimulation of macrophages causes the enzymatic breakdown of intracellular 
GTP to dihydroneopterin. This can diffuse from the cell and either be oxidised to 
neopterin in the presence of hypochlorous acid (HOCl) or to 7,8-dihydroxanthopterin in 
the presence of reactive oxygen species. Adapted from Gieseg et al. 2008. 
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HOCl is produced when myeloperoxidase catalyses its production from hydrogen 
peroxide and chloride ions in activated monocytes and neutrophiles (Reaction 8) H2O2 + 
Cl- + H+ = HOCl + H2O (Bergt et al., 2004; Han Kang et al., 2009; Heinecke, 1999; 
Widner et al., 2000). Myeloperoxidase is active in atherosclerotic lesions (Bergt et al., 
2004) which suggests 7,8-NP is directly oxidised to neopterin within the plaque. 
Neopterin is relatively stable and highly fluorescent, making it a good marker of immune 
cell activation (Widner et al., 2000). Due to its fluorescence, neopterin can be easily 
detected in the urine and plasma by HPLC analysis (Widner et al., 2000; Flavall et al., 
2008). Elevated neopterin levels occur in response to a wide range of infections, such as 
viral infection, bone marrow transplants, septicaemia, diabetes, cancers, HIV, arthritis, 
multiple sclerosis and atherosclerosis (Hamerlinck, 1999; Hoffmann et al., 2003). It has 
been observed that there are high correlations between neopterin increase and the 
severity of the inflammatory infection or malignant disease (Hoffmann et al., 2003).  
7,8-NP has been reported to act as both an antioxidant radical scavenger and a pro-
oxidative agent. 7,8-NP can be a potent scavenger of superoxide, peroxyl radicals (Baird 
et al., 2005; Duggan et al., 2002; Firth et al., 2008; Gieseg et al., 2003; Oettl et al., 1997) 
and nitrogen centred radicals (Oettl  et al., 2000). 
 
At micromolar concentrations 7,8-NP has been found to inhibit protein and lipid 
hydroperoxidation formation of LDL (Firth et al., 2008) as well as copper and peroxyl 
radical mediated LDL oxidation (Gieseg & Cato, 2003). The cell lines THP-1 and U937 
are both protected from AAPH derived peroxyl radicals with 7,8-NP (Baird et al., 2005). 
7,8-NP also protects U937 cells from Fe2+ and HOCl oxidation (Gieseg et al., 2003), as 
well as protein hydroperoxidation formation and peroxyl radical mediated thiol loss 
(Duggan et al., 2002). While at higher concentrations 7,8-NP acts as a pro-oxidant, it is 
able to induce apoptosis to several cells lines due to increased oxidative stress on the 
cells (Baier-Bitterlich et al., 1995; Baier-Bitterlich et al., 1997; Enzinger et al., 2002; 
Wirleitner et al., 2003). 7,8-NP has also been found to enhance hydrogen peroxide 
activity at a slightly alkaline pH (Weiss et al., 1993). The properties of 7,8-NP are 
therefore dependant on its concentration and chemical environment 
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1.4 Objective of this Study 
The aim of this study is to quantify the oxidant and antioxidant content of advanced 
atherosclerotic plaques and examine the relationships these markers have on each other 
and within their localisation along the plaque. Also explore the levels of neopterin and 
7,8-dihyroneopterin in patients with cardio heart disease. 
 
Many studies have identified the concentration of antioxidants and oxidation products 
within atherosclerotic plaques (Brown et al., 1997; Carpenter et al., 1993; Fu et al., 1998; 
Iuliano et al., 2003; Jachec et al., 2003; Micheletta et al., 2004; Nishi et al., 2002; Upston 
et al., 2002), but none have investigated these markers in respect to their spatial 
localisation along the length of the plaque or within respect to each other. Our laboratory 
has so far been the first to quantify the amount of neopterin in femoral and carotid 
plaques (Firth et al 2008; Gieseg et al., 2008). Within our laboratory fourteen plaques 
have been fully analysed, however due to this small sample size, the complexity and the 
differences in the plaques advanced diseased states, it has been difficult to obtain 
significant trends and correlations between the plaques. I have therefore analysed a 
further five plaques to hopefully begin to understand the potential relationships between 
the markers and where along the plaques certain markers may localise.  
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Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals 
 
All solutions were prepared using de-ionised and ultrafiltrated water from a NANOpure 
filtration system supplied by Barnstead/Thermolyne (IA, USA). All reagents used are of 
analytical grade or better, unless otherwise stated. 
 
Acetic acid (glacial) 
Acetone 
Acetonitrile 
Argon gas 
4-Aminobenzoic acid (ABA) 
Ammonium Phosphate dibasic minimum 98% 
Bicinchoninic acid (BCA) protein 
determination kit 
Bovine serum albumin (BSA) 
Butylated hydroxytoulene (BHT) 
Cholesterol reagent 
5-Cholesten-3B-ol-7-one 
Diethyl ether 
Diethylenetriaminepentaacetic acid (DTPA) 
7,8-Dihydroneopterin (7,8-NP) 
Ethanol 
Ethylenediaminetetraacetic acid (EDTA) 
n-Hexane 
Hydrochloric acid (HCl) 
Iodine 
L-3,4-Dihydroxyphenylalanine 
 
JT Baker, Mallinckrodt Baker Inc. 
Merck 
JT Baker 
BOC gasses, N.Z. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Pierce, U.S.A 
 
Sigma Chemical Co. 
Sigma Chemical Co. 
Roche Diagnostics, USA 
Sigma-Aldrich 
Merck 
Sigma Chemical Co. 
Schiricks Laboratory 
BDH Chemical Ltd 
BDH Chemical Ltd 
Unichrom, ARS 
Merck 
BDH Chemical Ltd 
Sigma Chemical Co. 
 
 
 
Materials and Methods 18
 
L-Ascorbic acid 
Mercaptoacetic acid 
Methanol 
2-(N-Morpholino)ethanesulfonic acid (MES) 
Neopterin 
Nitrogen gas 
Nitrogen liquid 
 
Orthophosphoric acid (85%) 
Phenol 
Potassium hydroxide 
Potassium iodide 
2-Propanol (isopropanol) 
Sodium acetate 
Sodium cyanoborohydride (NaCNBH3) 
Sodium dihydrogen phosphate monohydrate 
Sodium dodecyl sulphate (SDS) 
Sodium hydroxide 
1,1,3,3-Tetramethoxypropane 
2-Thiobarbituric acid, minimum 98% (TBA) 
α-Tocopherol 
Trichloracetic acid (TCA) 
Trifluroacetic acid (TFA) anahydrous 
Sigma Chemical Co. 
Sigma Chemical Co. 
Merck 
Sigma Chemical Co. 
Schiricks Laboratory 
BOC gasses, N.Z. 
Cryogenics, Department of Chemistry, 
University of Canterbury. 
BDH Chemical Ltd 
Sigma-Aldrich 
Merck 
Merck 
Merck 
Merck 
Fluka 
Scharlau Chemie S.A. 
Sigma-Aldrich 
Merck 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Merck 
Sigma Chemical Co. 
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2.1.2 HPLC Systems 
Two separate HPLC units were used during the research. HPLC system 1 (Shimadzu 
Corporation, Japan) consists of the controller SCL-10Avp, fluorescence detector RF-
10AXL, UV-Vis detector SPD-10A, autosampler SIL-10A, as well as column oven and 
degasser. HPLC system 2 (Shimadzu Corporation, Japan) consists of the controller 
CBM-20A, fluorescence detector RF-10AXL, diode array detector SPD-M20A, 
autosampler SIL-20ACHT, plus column oven and degasser. Peak areas were determined 
using LC solution software. 
 
2.1.3 HPLC Mobile Phase 
Salt based HPLC mobile phases were filtered through a 45 μm filter and all mobile 
phases were sonicated for 10 minutes before loading onto the HPLC. 
 
2.2 Methods 
2.2.1 Plaque Homogenisation 
Plaques were surgically removed at Christchurch Hospital by carotid or femoral 
endarterectomy on patients that had high-grade stenosis. It was generally possible to 
excise the plaque without entering the vessel lumen other than at the proximal and distal 
ends of the dissection. This usually preserved the luminal anatomy of the plaque and left 
the stenosis undisturbed within the excised specimen, leaving a “cast” of the plaque 
bifurcation. Once consent was given the excised plaques was placed on ice and 
immediately transported to the Free Radical Biochemistry Laboratory at The University 
of Canterbury where they were frozen at -80 and stored at -80 C. 
When ready for analysis the plaques were sectioned into 3-5 mm segments down their 
longitudinal axis while still frozen. Each section was numbered beginning at the end 
prior to the bifurcation and photographed. The sections were homogenised to a fine 
powder under liquid nitrogen, and weighted. Next 3.5 mL of water, 35 μL of 100 mg/mL 
EDTA and 35 μL of 20 mg/mL BHT (in methanol) was added, then vortexed to mix. The 
final volume for each section was noted. 
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2.2.2 Plasma Collection 
Blood samples were taken from patients with either chronic stable angina or suffering 
from an acute ST-elevation myocardial infarction while they where undergoing an 
angioplasty procedure at Christchurch Hospital. The first blood sample was taken from 
the femoral artery with more samples taken from in and around the culprit coronary 
artery using a low profile sampling catheter both before and after the blockage was 
removed. Twenty four hours following the procedure a 5ml blood sample was obtained 
from a forearm vein. Healthy volunteers each gave a 5 ml venous blood sample from the 
forearm. All samples were collected into EDTA tubes, iced immediately and shielded 
from the light. Whole blood was centrifuged at 1,200g at 4˚C for 10 minutes. The plasma 
was separated and acetonitrile added to give a 50:50 mix, this was then stored at – 80˚C 
for subsequent analysis.   
 
2.2.3 Cholesterol Determination 
This is a spectrophotomic assay based on a series of reactions involving the enzymes 
cholesterol esterase, cholesterol oxidase and peroxidise which results in the development 
of a red dye. The intensity of the dye is directly proportional to the concentration of total 
cholesterol within the sample. 10 μL of plaque homogenate was added to 1 mL of 
cholesterol reagent (CHOL, Roche Chemicals) and incubated in the dark for 10 minutes 
at room temperature. The absorbance was read at 500 nm against a cholesterol reagent 
blank. 
 
2.2.4 Protein Determination 
The protein content of a sample is determined using the BCA protein kit (Pierce, Illinois, 
USA). Bicinchonic acid (BCA) reacts with the protein to form a purple dye which is 
proportional to the protein concentration. Optimally, the protein concentration within the 
sample is required to be between 25 and 250 μg/mL therefore plaque homogenate was 
diluted with water by a factor of 10. 1 mL of freshly prepared working reagent in a 50:1 
ratio of reagents A:B (Reagent A sodium carbonate, sodium bicarbonate, BCA and 
sodium tartrate in 0.1 M sodium hydroxide and Reagent B 4% hydrated copper sulphate) 
was added to 50 μL of diluted plaque homogenate and placed on a heated block at 60ºC 
with gentle shaking for 30 minutes. The reaction was stopped by cooling samples on ice 
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before reading the absorbance at 562 nm against a water blank. Concentrations were 
determined from a BSA standard curve analysed by Prism (version 4.0, GraphPad 
Software, USA). 
 
2.2.5 Antioxidant Detection 
2.2.5.1 Pterin Assay 
The Pterin assay takes advantage of neopterin’s natural fluorescence allowing the 
detection and determination of neopterin and 7,8-dihydroneopterin (7,8-NP). To 
determine the 7,8-NP concentration it is oxidised to neopterin giving a total neopterin 
value, therefore subtracting the neopterin from the total neopterin gives the 7,8-NP 
concentration. Using reverse phase HPLC the accuracy of the assay is dependent on the 
removal of protein from the sample, as it has been shown that neopterin interacts with the 
proteins leading to an underestimation of its concentration (Flavall et al., 2008). Due to 
the labiality of 7,8-NP the pterin assay was preformed on the same day as the 
homogenisation of the plaque. 
 
For Plaque Homogenate  
For neopterin quantification the protein precipitation was induced by mixing 50 μL of 
ACN with 50 μL of plaque homogenate followed by vortexing and centrifugation at 
20,800g for 10 minutes at 4ºC. For total neopterin samples 50 μL of ACN was added to 
50 μL of plaque homogenate, vortexed and centrifuged as described above for 5 minutes. 
For the oxidation of 7,8-NP to neopterin 20 μL of acidic iodide (5.4%I2/10.8% KI in 1 M 
HCl) was added, vortexed and incubated in the dark for 15 minutes. This was followed 
by 20 μL of freshly prepared 0.6 M ascorbic acid to neutralise excess acidic iodide, and 
centrifuged as before for 10 minutes. 
 
From the neopterin and total neopterin supernatants, 10 μL was injected onto a reverse 
phase Synergi 4u Hydro-RP 80A, 250 x 4.6 mm column (Phenomenex) maintained at 
35ºC. The mobile phase of 20 mM ammonium phosphate pH 6.0 with 5% methanol 
mobile phase was pumped at a flow rate of 1 mL/minute and the neopterin detected at an 
excitation of 353 nm and emission 438 nm. 
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For Plasma Samples 
The frozen 50:50 plasma:ACN mix was defrosted under cold running water, followed by 
vortexing and centrifugation at 20,800g for 10 minutes at 4ºC. For the neopterin analysis, 
supernatant was taken directly from this ependorf and injected onto the HPLC as above. 
For the 7,8-NP samples 50 μL of the supernatant was placed into a separate ependorf 
with 10 μL of acidic iodide (5.4%I2/10.8% KI in 1 M HCl), vortexed and incubated in the 
dark for 15 minutes. 10 μL of freshly prepared 0.6 M ascorbic acid was then added to 
neutralise excess acidic iodide, then centrifuged at 20,800g for 10 minutes. The 
supernatant was injected onto the HPLC exactly the same as in the plaque homogenate 
samples. 
 
A standard neopterin stock stored at -20 ºC was prepared in 10 mM phosphoric acid and 
sonicated for 2 minutes. When required an aliquot was thawed and diluted to 50 nM with 
mobile phase. The 7,8-NP standard was prepared fresh in mobile phase and kept on ice 
and in the dark to minimise loss. 
 
2.2.5.2 α-Tocopherol Assay 
α-Tocopherol is a lipid soluble antioxidant due to its long hydrocarbon chain and 
efficient peroxyl radical scavenging properties. It has a cyclic structure which is 
important for its antioxidant activity and also allows its detection at 292 nm. 
 
Within 10 mL glass culture tubes with screw tops 100 μL of plaque homogenate was 
diluted with 400 μL of water. To prevent any additional oxidation occurring 10 μL of 100 
mg/mL EDTA and 25 μL of 20 mg/mL BHT (in methanol) was added. Protein 
precipitation was induced with 500 μL of ice cold ethanol and vortexed for 10 seconds. 
The α-tocopherol was extracted by adding 2 mL of hexane with further vortexing for 30 
seconds. At this point the samples were stored a -80ºC until needed for analysis. Once 
thawed the samples were vortexed for 60 seconds before centrifuging at 600g for 5 
minutes to maximise phase separation. 1.4 mL of the hexane layer was transferred into 
glass tapered 10 mL tubes and evaporated in a hot water bath under nitrogen gas. The 
remaining residue was dissolved in 100 μL ice cold methanol and injected onto the 
HPLC. 
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With a mobile phase of 100% methanol, 20 μL sample was injected onto a reverse phase 
Phenosphere-NEXT C-18, 150 x 4.6 nm, 5 μm column (Phenomenex) maintained at 
35ºC, and detected at an extinction of 292 nm and emission of 353 nm. The α-tocopherol 
standard was prepared by diluting approximately 1 mg/mL α-tocopherol in methanol and 
the concentration determined spectrophotometrically using an extinction coefficient of 
3086 cm-1M-1 at a wavelength of 294 nm. The α-tocopherol standard stock solution was 
stored at -20ºC under argon gas and when required was diluted to a 3 μM concentration 
in methanol. 
 
2.2.6 Lipid Oxidation Measurement 
2.2.6.1 TBARS Assay 
The TBARS assay provides a general measurement of fatty acid oxidation occurring 
within biological systems. One of the breakdown products of lipid oxidation is 
malondialdehyde (MDA). The well established 2-thiobarbitutic (TBA) reaction with 
MDA yields a pink colour that is detected at 553 nm 
 
Into a 1.75 mL centrifuge tube 100 μL of plaque homogenate was placed, with 50 μL of 
150 mM phosphoric acid to increase the acidity and precipitate the protein, 10 μL of 20 
mg/mL BHT (in methanol) was added to prevent further oxidation and the samples were 
stored at -80ºC. When ready for analysis 50 μL of freshly prepared 42 mM TBA was 
added to the thawed samples and placed on a heated block at 95 ºC with gentle shaking 
for 30 minutes allowing the formation of the TBA-MDA adduct. The samples were 
cooled on ice, 800 μL of cold methanol was then added, incubated on ice for a further 5 
minutes and centrifuged at 20,800g for 10 minutes at 4 ºC. To equilibrate the sample to 
the mobile phase 100 μL of the supernatant was added to 100 μL of 50 mM NaH2PO4 pH 
6.8 and injected onto the HPLC.  
 
The HPLC mobile phase was 50 mM NaH2PO4 pH 6.8 with 45% methanol at a flow rate 
of 1 mL/minute through a reverse phase Phenosphere C-18, 4.6 x 150 mm, 5 μm column 
(Phenomenx) heated to 35ºC. The TBA-MDA was detected at an excitation of 525 nm 
and emission of 550 nm. Both blank and 1 μM TBA-MDA standards were required to 
determine the concentration of TBARS within the samples. 
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MDA is very labile, therefore the standard was freshly prepared with each sample block 
by incubating a known concentration of the MDA precursor 1,1,3,3-tetramethoxypropane 
with TBA. 1,1,3,3-tetramethoxypropane hydrolyses to MDA during the heated 
incubation step forming a known concentration of TBA-MDA. During preparation of the 
standard the first dilution step of 1,1,3,3-tetramethoxypropane was in a solution of 
ethanol:water at a 2:3 ratio, where further dilutions were made in water. 
 
2.2.6.2 Combined 7-Ketocholesterol and α-Tocopherol Assay 
To reduce the amount of homogenate used in the plaque analysis a modified procedure 
was developed to measure both 7-ketocholesterol and α-tocopherol with one injection 
onto the HPLC. 
 
The 7-ketocholesterol concentration was determined for both the free 7-ketocholesterol 
and the total 7-ketocholesterol (free plus esterified). For both the free and total 7-
ketocholesterol 100 μL plaque homogenate was diluted in 400 μL water, to prevent 
additional oxidation 10 μL of 20 mg/mL BHT (in methanol) and 20 μL of 100 mg/mL 
EDTA was added. Protein precipitation was induced by 500 μL of cold ethanol and 
vortexed briefly. The 7-ketocholesterol and α-tocopherol was extracted by the addition of 
2 mL hexane, vortexed for 30 seconds and this was then stored at -80ºC until required for 
analysis. Once thawed the samples were vortexed for 60 sections and centrifuged at 600g 
for 5 minutes at 4ºC. 1.4 mL of the hexane layer was transferred into glass tapered 10 mL 
tubes and evaporated in a hot water bath under oxygen free nitrogen gas. For free 7-
ketocholesterol and α-tocopherol analysis the remaining residue was dissolved in 100 μL 
ACN:isopropanol at a 4:5 ratio, and injected onto the HPLC. For total 7-ketocholesterol 
analysis the remaining residues was dissolved in 2 mL 20% KOH (in methanol) plus 2.5 
mL diethyl ether, then placed under argon gas and vortexed. The samples were incubated 
on ice for 3 hours, with a brief vortex every 30 minutes. The reaction was then stopped 
by adding 2 mL 20% acetic acid and 2.5 mL hexane and vortexed for 60 seconds. 4 mL 
of the upper layer was transferred into glass tapered 10 mL tubes and dried down under 
oxygen free nitrogen gas, before re-solubilising in 100 μL of mobile phase. 
 
20 μL of the samples was injected onto a Phenosphere-NEXT C18, 250 x 4.6 mm, 5 μm 
column (Phenomenex) maintained at 35ºC pumping a mobile phase of 54 isopropanol:44 
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acetonitrile:2 water at 1 mL/min. The elute first ran through the UV detector for the 
detection of 7-ketocholesterol at a wavelength of 234 nm, and continued on through to 
the fluorescence detector set at an excitation of 292 nm and emission of 335 nm for the 
detection of α-tocopherol. 
 
The α-tocopherol standard was prepared by diluting approximately 1 mg/mL α-
tocopherol in methanol and the concentration determined spectrophotometrically using 
an extinction coefficient of 3086 cm-1M-1 at a wavelength of 294 nm. The α-tocopherol 
standard stock solution was stored at -20ºC under argon gas and when required was 
diluted to a 3 μM concentration in methanol. The 7-ketocholesterol standard was 
prepared in the mobile phase and diluted to 10µM in a ACN:isopropanol solution at a 4:5 
ratio. 
 
2.2.7 Protein Oxidation Detection 
2.2.7.1 DOPA and Dityrosine Assay 
DOPA and Dityrosine are oxidative products derived from the tyrosine residue. HPLC 
analysis is able to separate the products after their release from the protein and allows the 
detection of both these protein oxidative products with one assay. 
 
Into 7.5 mm glass durham tubes was placed 10 μL of 100 mg/mL EDTA, 10 μL of 20 
mg/mL BHT (in methanol) and 100 μL of plaque homogenate. The protein was 
precipitated by the addition of 900 μL of ice cold acetone and incubated on ice for 10 
minutes followed by centrifugation at 5000g at 4ºC  for 15 minutes. The supernatant was 
removed and the pellet washed with 500 μL diethyl ether to remove lipids and 
centrifuged as before. After the removal of the supernatant the pellets were dried under 
vacuum for 1 hour and then placed into pico-Tag vials (Millipore, USA) with 1 mL of 6 
M HCl with 1% (w/v) phenol and 50 μL mercaptoacetic acid in each vial. The vials were 
flushed with argon gas for 5 minutes and evacuated by connecting to the vacuum line of 
the solvent Speed Vac for 2 seconds. For the acid hydrolysis of the proteins the vials 
were incubated in a 110ºC oven for 16 hours. After cooling, the samples were 
centrifuged under vacuum in the Speed Vac for 2 hours before re-solubilising the pellet 
with 200 μL of 0.1% TFA. The samples were vortexed and transferred into ependorf 
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tubes to enable centrifugation at 20,800g for 10 minutes at 4ºC before injecting onto the 
HPLC.  
Using a reverse phase Aqua C18, 250 x 4.6 mm, 5 μm column (Phenomenex) 10 μL of 
the acid hydrolysate was injected with a gradient mobile phase pumping at 1 mL/minute. 
The gradient began a 99% 0.1% TFA pH 2.5 with 1% ACN, with the ACN increasing to 
5% by the 10th minute, 10% by the 14th minute and 50% by the 16th minute. This 
concentration was maintained for 5 minutes to clean the column, after which the ACN 
concentration was returned and maintained at 1% until the 30th minute. Because DOPA 
elutes first the fluorescence detector began at an excitation of 280 nm and an emission of 
320 nm. At the 11th minute the emission is changed to 410 nm for the detection of 
Dityrosine. The DOPA standard was prepared fresh and a Dityrosine standard stock is 
stored at -20ºC, both were made up and diluted in 0.1% TFA. 
 
2.2.7.2 Protein Carbonyls AAS and GGS HPLC Assay 
This method detects two of the main protein carbonyl products, α-aminoadipic 
semialdehyde (AAS) and γ-glutamic semialdehyde (GGS). AAS and GGS accounts of 
23% of the total carbonyls within native BSA (Akagawa et al, 2006). 
 
The samples were prepared in glass durham tubes with 200 μL plaque homogenate, to 
prevent further oxidative events 50 μL of 1 mM DTPA was added followed be 50 μL of 
50% TCA to precipitate proteins. The samples were kept on ice for 10 minutes then 
centrifuged for 10 minutes at 500g at 4ºC. The supernatant was removed and using a 
sealed pasture pipette as a stirring rod the protein pellet was re-suspended in 125 μL of 
0.25 M MES buffer pH 6.0 with 0.5% SDS. To the mixture 250 μL of the highly 
fluorescent 50 mM ABA in MES buffer and 125 μL of 100 mM NaCNBH3 in MES 
buffer was added and the tubes were briefly vortexed before incubating in the dark at 
37ºC at 80 rpm for 90 minutes, allowing the ABA to react with the AAS and GGS. After 
the samples were cooled on ice the protein was precipitated with 500 μL of ACN, 
incubated on ice for 10 minutes and centrifuged at 500g at 4ºC for 15 minutes. To ensure 
the protein was precipitated, the supernatant was removed and the pellet washed with 1 
mL 10% TCA and centrifuged as before. The supernatant was removed once again and 
the pellet re-suspended in 1 mL of cold ethanol and spun as before. For the final time the 
supernatant was removed and the residual ethanol drained off by inverting the tubes for 5 
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minutes. The pellets were dried under vacuum for 1 hour before placing them into Pico-
Tag vials with 1.5 ml 6 M HCl for acid hydrolysis. Air was flushed out using argon gas 
for 5 minutes before the vials were evacuated by connecting to the vacuum line of a 
solvent Speed Vac for 2 seconds. For the acid hydrolysis of the proteins the vials were 
incubated in a 110ºC oven for 24 hours. After cooling, the samples were centrifuged 
under vacuum in the Speed Vac for 2 hours before re-solubilising the pellet with 200 μL 
of 50 mM sodium acetate pH 5.4. The samples were vortexed and transferred into 
ependorf tubes to enable centrifugation at 20,800g for 10 minutes at 4ºC before injecting 
onto the HPLC.  
 
Onto a reverse phase Synergi Fusion 250 x 4.6 mm, 4 μm column (Phenomenex) with a 
gradient mobile phase pumping at 1 mL/minute, 20 μL of each sample was injected. The 
mobile phase began at 95% of 50 mM sodium acetate pH 5.4 and 5% ACN and was 
maintained until the 20th minute. The ACN concentration increased reaching 50% by the 
25th minute and this was maintained for 5 minutes to clean the column, after which the 
ACN concentration was returned to 5% for the remainder of the run (40 minutes). The 
AAS-ABA and GGS-ABA compounds were detected at an excitation of 283 nm and an 
emission of 350 nm. For the standard, ABA was prepared in mobile phase, sonicated for 
2 minutes and injected at a concentration of 1 μM. 
 
2.3 Statistical Analysis 
Unless otherwise stated, the data shown represents the mean ± the standard error of the 
mean (SEM) of triplicates for each section. The SEM is represented on each bar and data 
point within the graphs. The statistical analysis was preformed using Prism (version 4.0 
and version 5.0, Graphpad Software, USA) and Statistica (version 9.0 Statsoft, Inc, 
USA). Statistical significance are represented by * (P<0.05), **(P<0.01) and *** 
(P<0.001). 
 
Comparisons between the individual sections in each plaque were preformed by one-way 
analysis of variance (ANOVA) followed by the Tukey’s multiple comparison test to 
designate significant variations between the means.  Statistics on the correlation data was 
preformed using Statistica's correlation matrices. All statistics on the human plasma data 
used one-way ANOVA followed by the Tukey’s test. 
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2.4 Ethics Approval 
Ethics approval for access to patient information and analysis of atherosclerotic plaques 
was granted from the Upper South A Regional Ethics Committee, ethics number 
CTY/01/04/036. Under this agreement consent from the donor was obtained and the 
plaques remained anonymous from the donor labelled by a laboratory based code. 
 
Collection of blood from patients undergoing angioplasty was approved by the Upper 
South A Regional Ethics Committee, part of the Health Research Council, administered 
through the New Zealand Ministry of Health (Ethics Reference: URA/05/08/097). The 
period of patient enrolment was October 2007 – March 2009. All patients and controls 
provided written consent prior to enrolment and were fully informed of the study design 
and methods 
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Results 
3.1 Atherosclerotic Plaques 
All atherosclerotic plaques were received from patients undergoing carotid or femoral 
endarterectomy and were in an advanced stage of the disease. The plaques were cut into 
3-5 mm long sections beginning in the direction of the blood flow. During 
homogenisation, the plaques were qualitatively assessed on their morphology and overall 
composition, including the degree of calcification and the presence of ‘gruel’, large areas 
of the lipid core.  
 
Because the level of shear stress may play a role in the formation, progression and 
rupture of these plaques (Chatzizisis et al., 2007), each plaque section was classified into 
zones based on its location along the plaque. These zones represent the pre-bifurcation, 
bifurcation and post-bifurcation regions.  The zones may be under different levels of 
shear stress and therefore represent potentially different oxidative environments. The 
zoning also allows for standardisation of each plaque for a combined plaque analysis. 
 
Within each plaque section of the five atherosclerotic plaques a range of markers were 
measured. These markers included the inflammatory marker neopterin, as well as total 
pterin (neopterin plus 7,8-dihydroneopterin), lipid soluble antioxidant α-tocopherol, the 
general lipid oxidation marker TBARS, the oxysterol 7-ketocholesterol, protein oxidation 
markers DOPA, Dityrosine, and protein carbonyls AAS and GGS, along with protein and 
total cholesterol.  
 
In the plaque profile graphs the clear bars represent the section/s from the pre-bifurcation 
zone, the solid filled bars from the bifurcation zone and the stripped bars represent the 
section/s from the post-bifurcation zone. Statistical analysis was carried out on all the 
marker analysis data, with an asterisk placed on the top of any bar/point to indicate a 
statistically significant change in the concentration of a section from the previous section. 
* represents (P<0.05), ** (P<0.01) and *** (P<0.001). 
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3.1.1 Plaque A (Plaque Laboratory No 17) 
Plaque A was removed from the left carotid artery. It was characterised with over 90% 
stenosis, 38 mm in length and weighed a total mass of 1.179 grams. In overall 
composition, this plaque was soft with only slight calcification in section 6 (Figure 
3.1.1). Plaque A was cut into 9 sections where sections 1-2 were the pre-bifurcation zone, 
sections 3-4 were the bifurcation and sections 5-9 were the post-bifurcation zone. 
 
Table 3.1.1 Plaque A Patient and Clinical Information 
Location                 Left Carotid Artery                     Stenosis             >90% 
Symptoms              Transient Ischemic Attacks         Gender              M 
Smoking Status      Ex-smoker                                   Age                    69 
Medications           Simvastatin, Felate, Quinapril, Warfrin, Thiamine, Omeprazole 
 
 
Figure 3.1.1 Sectioning and Zones of Plaque A 
Plaque A was removed from the left carotid artery and cut into 9 sections each of which 
was homogenised. Sections 1-2 were the pre-bifurcation zone, sections 3-4 were the 
bifurcation zone and sections 5-9 were the post-bifurcation zone. Top right hand insert 
not to scale. 
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Figure 3.1.2 Protein, Cholesterol, Neopterin and α-Tocopherol Content in Plaque A 
Protein (a) and cholesterol (b) concentrations were determined spectrophotometrically, 
while the neopterin (c) and α-tocopherol (d) were quantified by reverse phase HPLC. The 
clear bars represent the pre-bifurcation zone, solid bars the bifurcation zone and stripped 
bars the post-bifurcation zone. Each bar represents the mean ± SEM of the analysis from 
triplicate samples. 
 
 
The protein content in plaque A showed a significant decrease between section 1 and 2 
(P<0.05), it then remained similar throughout the remaining sections of the plaque until 
there was a large rise in the final section (Figure 3.1.2a). The cholesterol concentration 
showed a highly significant increase between the bifurcation and post-bifurcation zones 
(P<0.001). The highest level of cholesterol was found in section 7 with a sudden decrease 
in concentration in sections 8 and 9 (Figure 3.1.2b). There was significant variations in 
the neopterin concentration along the length of plaque A with decreases (P<0.001) in the 
concentration for the first section of both the bifurcation and post-bifurcation zones 
(sections 3 and 5 respectively). The highest concentration of neopterin was found in the 
last section of the plaque (Figure 3.1.2c). The α-tocopherol concentration followed a 
similar trend to that of cholesterol with the highest concentration found in section 7 at 
270.92 ± 10.38 nmoles/g plaque (Figure 3.1.2d) 
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Figure 3.1.3 Lipid and Protein Oxidation Markers in Plaque A 
TBARS (a) protein carbonyls AAS and GGS (b) DOPA (c) and dityrosine (d) were all 
quantified via reverse phase HPLC. Clear bars represent the pre-bifurcation zone, solid 
bars the bifurcation zone and stripped bars the post-bifurcation zone in graphs (a), (c) and 
(d). The lines underneath the bars in graph (b) indicate the separate zones. Each bar 
represents the mean ± SEM of the analysis from triplicate samples. 
 
Plaque A’s TBARS content showed a decrease in concentration between the pre-
bifurcation and bifurcation zones (P<0.01), and a highly significant rise from section 6 to  
7 (Figure 3.1.3a). The highest concentration of protein carbonyls AAS and GGS was 
found in section 1, with significant decreases down in section 2, 3 and 4 (P<0.001). Apart 
from a rise in section 6’s AAS, both the protein carbonyls concentrations remained stable 
throughout the post-bifurcation zone until increasing sharply in section 9 (Figure 3.1.3b). 
The DOPA concentrations remained at a consistent level across all sections of plaque A 
(Figure 3.1.3c). There was no dityrosine detectable in the pre-bifurcation zone of plaque 
A, nor was there any in sections 4 and 9. The majority of dityrosine was found in the 
post-bifurcation zone with the highest concentration of 11.58 ± 0.22 in section 6 (Figure 
3.1.3c). Strong correlations in trends across sections can be seen between cholesterol, α-
tocopherol and dityrosine with low concentrations in the pre-bifurcation and bifurcation 
zones and an increasing concentration in the middle of the post bifurcation zone of all 
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three markers. A significant decrease in concentration between the pre-bifurcation and 
bifurcation zone occurred in four of the eight markers analysed (neopterin, TBARS, AAS 
and GGS protein carbonyls). Four markers (protein, neopterin, AAS and GGS protein 
carbonyls) also had a significant increase in the concentration of section 9. 
 
3.1.2 Plaque B (Plaque Laboratory No 19) 
Plaque B was removed from the left carotid artery. It was characterised with 75% 
stenosis, 26 mm in length and weighed a total mass of 0.406 grams. A very clear 
secondary branch was seen with both openings visible in section 4 (Figure 3.1.4). The 
majority of the stenosis was seen in the post-bifurcation sections 5 and 6. Plaque B 
showed no signs of calcification. 
 
Table 3.1.2 Plaque B Patient and Clinical Information 
Location                 Left Carotid Artery                     Stenosis             75% 
Symptoms              Stoke                                           Gender              M 
Smoking Status      Ex-smoker                                  Age                    68 
Medications           Omeprazole, Enalapril, Pentasa, Aspirin, Simvastatin 
 
 
Figure 3.1.4 Sectioning and Zones of Plaque B 
Plaque B was removed from the left carotid artery and cut into 6 sections, each of which 
was homogenised. Sections 1-2 were the pre-bifurcation zone, sections 3-4 were the 
bifurcation zone and sections 5-6 were the post-bifurcation zone. Top right hand insert 
not to scale. 
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Figure 3.1.5 Protein, Cholesterol, Neopterin and α-Tocopherol Content in Plaque B 
Protein (a) and cholesterol (b) concentrations were determined spectrophotometrically, 
while the neopterin (c) and α-tocopherol (d) were quantified by reverse phase HPLC. The 
clear bars represent the pre-bifurcation zone, solid bars the bifurcation zone and stripped 
bars the post-bifurcation zone. Each bar represents the mean ± SEM of the analysis from 
triplicate samples. 
 
 
The highest protein concentration in plaque B was in section 2 at 189.49 ± 10.72 mg/g 
plaque, followed by a significant decrease in the bifurcation zone (Figure 3.1.5a). The 
cholesterol content showed the opposite trend, there was a significant increase in the 
concentration between the pre-bifurcation and bifurcation zones, and also a highly 
significant decrease (P<0.001) in the last section (Figure 3.1.5b). Neopterin levels were 
below the detectable limit in plaque B (Figure 3.1.5c). Although the α-tocopherol content 
showed no significant variation between neighbouring sections 1 to 5, there did appear to 
be a general increase in concentration peaking at 129.57 ± 5.49 in section 5, followed by 
a dramatic decrease in section 6 (Figure 3.1.5d).   
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Figure 3.1.6 Lipid and Protein Oxidation Markers in Plaque B 
TBARS (a) 7-ketocholesterol (b) protein carbonyls AAS and GGS (c) DOPA (d) and 
dityrosine (e) were all quantified via reverse phase HPLC. Clear bars represent the pre-
bifurcation zone, solid bars the bifurcation zone and stripped bars the post-bifurcation 
zone in graphs (a), (d) and (e). The lines underneath the bars in graph (b) and (c) indicate 
the separate zones. Each bar represents the mean ± SEM of the analysis from triplicate 
samples. 
 
 
The pre-bifurcation zone of plaque B contained significantly higher amounts of TBARS 
compared to both the bifurcation and post-bifurcation zones (Figure 3.1.6a). The opposite 
trend to this was seen in the DOPA content, where DOPA was below the detection limit 
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in the pre-bifurcation zone and at a steady concentration throughout the rest of the plaque 
(Figure 3.1.6d). 7-Ketocholesterol showed no correlation between the concentrations of 
free and total 7-KC, the levels of both varied dramatically across the length of the plaque 
(Figure 3.1.6b). Both protein carbonyls in plaque B remained at relatively consistent 
concentrations across the plaque, with the AAS concentrations always significantly 
higher than the GGS concentrations (Figure 3.1.6c). The dityrosine levels in plaque B 
were low across sections 1, 2 and 3, dropping below the detection limit in section 4 
before they increased significantly in the post-bifurcation zone (P<0.001) (Figure 3.1.6e). 
Trends seen in plaque B showed a significant decrease between the pre-bifurcation and 
bifurcation zones in protein, TBARS, free 7-KC and AAS protein carbonyl. Section 6 
contained the lowest concentration of four of the markers, cholesterol, α-tocopherol, 
AAS and GGS protein carbonyls, while there was a significant increase between the pre-
bifurcation and bifurcation zones of cholesterol and DOPA. 
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3.1.3 Plaque C (Plaque Laboratory No 21) 
Plaque C was removed from the left carotid artery. It was 28 mm in length, weighed total 
mass of 0.167 grams and had 90% stenosis. There was only a very small secondary 
branch in section 1 making this the bifurcation section (Figure 3.1.7). All remaining 
sections were in the post-bifurcation zone. Plaque C had no pre-bifurcation sections, no 
calcification and no thrombus present 
 
Table 3.1.3 Plaque C Patient and Clinical Information 
Location                 Left Carotid Artery                     Stenosis             90% 
Symptoms              Stoke                                          Gender               F 
Smoking Status     Non-smoker                                Age                    63 
Medications          Aspirin, Cilazapril, Simvastatin, Fluticasone inhaler 
 
 
Figure 3.1.7 Sectioning and Zones of Plaque C 
Plaque C was removed from the left carotid artery and cut into 4 sections, each of which 
was then homogenised. Section 1 was the bifurcation zone and sections 2-4 were the 
post-bifurcation zone. Top right hand insert not to scale 
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Figure 3.1.8 Protein, Cholesterol, Neopterin and α-Tocopherol Content in Plaque C 
Protein (a) and cholesterol (b) concentrations were determined spectrophotometrically, 
while the neopterin (c) and α-tocopherol (d) were quantified by reverse phase HPLC. In 
graphs (a), (b) and (d) clear bars represent the pre-bifurcation zone, solid bars the 
bifurcation zone and stripped bars the post-bifurcation zone. The lines underneath the 
bars in graph (c) indicate the separate zones. Each bar represents the mean ± SEM of the 
analysis from triplicate samples. 
 
 
 
The protein content showed no significant changes between neighbouring sections of 
plaque C and had an average concentration of 119.93 ± 16.41 mg/g plaque (Figure 
3.1.8a). The bifurcation zone contained a significantly lower cholesterol content then the 
post-bifurcation zone (P<0.001) (Figure 3.1.8b). Neopterin was undetectable in plaque C 
but the total pterin content was constant throughout the length of the plaque, indicating 
that only 7,8-dihydroneopterin was present in this plaque at an average concentration of 
993.42 ± 59.95 pmoles/g plaque (Figure 3.1.8c). Plaques C’s α-tocopherol content 
showed a similar trend to that of cholesterol, with the bifurcation section having a 
significantly lower concentration (Figure 3.1.8d).  
Results 39
 
1 2 3 4
0
5
10
15
20
25
30
35
d)
Plaque section
D
O
PA
 (n
m
ol
e/
g 
pl
aq
ue
)
1 2 3 4
0
1
2
3
4
5
6
7
8
e)
Plaque section
D
ity
ro
si
ne
 (n
m
ol
es
/g
 p
la
qu
e)
 
Figure 3.1.9 Lipid and Protein Oxidation Markers in Plaque C 
TBARS (a) 7-ketocholesterol (b) protein carbonyls AAS and GGS (c) DOPA (d) and 
dityrosine (e) were all quantified via reverse phase HPLC. In graphs (a), (d) and (e) clear 
bars represent the pre-bifurcation zone, solid bars the bifurcation zone and stripped bars 
the post-bifurcation zone. The lines underneath the bars in graphs (b) and (c) indicate the 
separate zones. Each bar represents the mean ± SEM of the analysis from triplicate 
samples. 
 
 
 
The TBARS concentration remained constant across all sections of plaque C (Figure 
3.1.9a). Although the free 7-ketocholesterol levels in the plaque did not vary 
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significantly, there was a decrease in concentration of total 7-ketocholesterol between 
sections 2 and 3 resulting in the last two sections of plaque C having lower total 7-KC 
(Figure 3.1.9b). The protein carbonyls showed a small rise in AAS content in sections 3 
and 4 but no change in the GGS concentrations across the plaque sections (Figure 
3.1.9c). Both DOPA and dityrosine had no statistical variation in their content across the 
plaque, with average concentrations of 24.69 ± 3.31 nmoles/g plaque and 5.76 ± 0.55 
nmoles/g plaque respectively (Figure 3.1.9d and Figure 3.1.9e). With the exceptions of 
cholesterol and α-tocopherol that had significantly lower concentrations in the bifurcation 
zone, Plaque C showed a stable and consistent distribution in most of the markers across 
all sections. This indicates no chemical differences between the bifurcation and post-
bifurcation zones within this plaque. 
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3.1.4 Plaque D (Plaque Laboratory No 23) 
Plaque D was removed from the right carotid artery. It was characterised with 60 – 79% 
stenosis, 31 mm in length and weighed a total mass of 0.536 grams. In overall 
composition, this plaque had a small secondary branch, substantial fatty ‘gruel’ deposits 
in section 4, 5 and 6, as well as very small areas of calcification along the plaque (Figure 
3.1.10).  
 
Table 3.1.4 Plaque D Patient and Clinical Information 
Location                 Right Carotid Artery                   Stenosis             60 - 79% 
Symptoms              Stoke                                           Gender              M 
Smoking Status     Non-smoker                                Age                    70 
Medications          Aspirin, Metoprolol, Simvastatin, Omeprazole, Dipyridamole, 
                              Cilazapril 
 
 
Figure 3.1.10 Sectioning and Zones of Plaque D 
Plaque D was removed from the right carotid artery and cut into 6 sections, each of 
which was homogenised. Sections 1-2 were the pre-bifurcation zone, sections 3-4 were 
the bifurcation zone and sections 5-6 were the post-bifurcation zone. Top right hand 
insert not to scale. 
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Figure 3.1.11 Protein, Cholesterol, Neopterin and α-Tocopherol Content in Plaque 
D 
Protein (a) and cholesterol (b) concentrations were determined spectrophotometrically, 
while the neopterin (c) and α-tocopherol (d) were quantified by reverse phase HPLC. In 
graphs (a), (b) and (d) clear bars represent the pre-bifurcation zone, solid bars the 
bifurcation zone and stripped bars the post-bifurcation zone. The lines underneath the 
bars in graph (c) indicate the separate zones. Each bar represents the mean ± SEM of the 
analysis from triplicate samples. 
 
 
The highest concentration of protein in plaque D was in section 1 (346.49 ± 13.80 mg/g 
plaque) followed by a highly significant decrease in section 2 and across the remaining 
sections of the plaque (Figure 3.1.11a). Plaque D’s cholesterol content showed a general 
trend downwards from section 1 to 4, with the concentration increasing significantly 
(P<0.001) in both sections of the post-bifurcation zone (Figure 3.1.11b). Neopterin levels 
were significantly high in section 1 at 199.75 ± 17.05 pmoles/g plaque, the concentration 
remained at a lower level throughout the rest of the plaque. The total pterin levels were 
only greater than the neopterin levels in section 4 and 5, indicating that 7,8-
dihydroneopterin was only present in these two sections. Section 5, the first post-
bifurcation section, contained a vast amount of total pterin (782.67 ± 68.50 pmoles/g 
plaque) compared to the other sections (Figure 3.1.11c). The α-tocopherol content in 
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plaque D remained at a constant level over the first 5 sections but increased significantly 
(P<0.001) in the last section (Figure 3.1.11d) 
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Figure 3.1.12 Lipid and Protein Oxidation Markers in Plaque D 
TBARS (a) 7-ketocholesterol (b) protein carbonyls AAS and GGS (c) DOPA (d) and 
dityrosine (e) were all quantified via reverse phase HPLC. In graphs (a), (d) and (e) clear 
bars represent the pre-bifurcation zone, solid bars the bifurcation zone and stripped bars 
the post-bifurcation zone. The lines underneath the bars in graphs (b) and (c) indicate the 
separate zones. Each bar represents the mean ± SEM of the analysis from triplicate 
samples. 
 
The TBARS content showed a similar trend to that of the protein content in plaque D 
with section 1 containing a significantly higher concentration than the rest of the plaque 
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(Figure 3.1.12a). Section 1 was also significantly high (P<0.001) in both free and total 7-
KC content, the concentration decreased in section 2 and remained lower across the rest 
of the plaque. There was an increase in total 7-KC concentration between the bifurcation 
and post-bifurcation zones (Figure 3.1.12b). Both protein carbonyls AAS and GGS had a 
significant decrease in concentration from the pre-bifurcation zone to the bifurcation 
zone (Figure 3.1.12c). This decrease in concentration at the bifurcation zone was also 
seen in the DOPA content of plaque D (Figure 3.1.12d). There was no significant 
changes in the dityrosine concentration between sections 1 to 5 but it decreased 
significantly (P<0.001) in section 6 (Figure 3.1.12e). The major trends seen in this plaque 
were a significant decrease in concentration between sections 1 and 2 occurring in a total 
of six markers (protein, cholesterol, neopterin, TBARS, free 7-KC and total 7-KC). All 
the oxidation markers (Figure 3.1.12) showed a decrease in concentration between the 
pre-bifurcation and bifurcation zones, while both cholesterol and α-tocopherol had a 
significant increase in their concentrations at the post-bifurcation zone.   
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3.1.5 Plaque E (Plaque Laboratory No 23) 
Plaque E was from a right carotid artery. It was 30 mm in length, weighed a total mass of 
0.914 grams and had 60% stenosis. This plaque had a large secondary branch which 
covered three sections, while no no calcification was found all sections contained large 
amounts of ‘gruel’ (Figure 3.1.13).  
 
Table 3.1.5 Plaque E Patient and Clinical Information 
Location                 Right Carotid Artery                   Stenosis             60% 
Symptoms              Transient Ischemic Attacks         Gender              M 
Smoking Status     EX-smoker                                  Age                    73 
Medications           Aspirin, Dipyridamole, Quinapril, Accuretic, Ezetimibe,  
                               Felodipine ER, Atenolol, Protophane, Novorapid 
      
 
 
Figure 3.1.13 Sectioning and Zones of Plaque E 
Plaque E was removed from the right carotid artery and cut into 6 sections, each of which 
was homogenised. Sections 1-2 were the pre-bifurcation zone, sections 3-5 were the 
bifurcation zone and section 6 was the post-bifurcation zone. Top right hand insert not to 
scale. 
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Figure 3.1.14 Protein, Cholesterol, Neopterin and α-Tocopherol Content in Plaque 
E 
Protein (a) and cholesterol (b) concentrations were determined spectrophotometrically, 
while the neopterin (c) and α-tocopherol (d) were quantified by reverse phase HPLC. In 
graphs (a), (b) and (d) clear bars represent the pre-bifurcation zone, solid bars the 
bifurcation zone and stripped bars the post-bifurcation zone. The lines underneath the 
bars in graph (c) indicate the separate zones. Each bar represents the mean ± SEM of the 
analysis from triplicate samples. 
 
 
Plaque E’s protein content was consistent throughout most sections of the plaque with 
only a decrease in concentration in the post-bifurcation zone (Figure 3.1.14a). The 
cholesterol content in this plaque showed a general trend of increasing concentration in 
the pre-bifurcation and bifurcation zones, although the only significant increase in 
concentration was in section 4. There was also a significant decrease in the cholesterol 
content in the post-bifurcation zone (Figure 3.1.14b). The total pterin concentrations 
were significantly higher in section 2 and 3, reaching the highest concentration of 363.63 
± 4.75 pmoles/g plaque in section 3. Section 3 contained the highest concentration of 
neopterin as well (Figure 3.1.14c). α-Tocopherol showed a very similar trend to 
cholesterol, with a significant increase in concentration between sections 3 and 4, and 
again a decrease in concentration in section 6, the post-bifurcation zone (Figure 3.1.14d) 
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Figure 3.1.15 Lipid and Protein Oxidation Markers in Plaque E 
TBARS (a) 7-ketocholesterol (b) protein carbonyls AAS and GGS (c) DOPA (d) and 
dityrosine (e) were all quantified via reverse phase HPLC. In graphs (a), (d) and (e) clear 
bars represent the pre-bifurcation zone, solid bars the bifurcation zone and stripped bars 
the post-bifurcation zone. The lines underneath the bars in graphs (b) and (c) indicate the 
separate zones. Each bar represents the mean ± SEM of the analysis from triplicate 
samples. 
 
 
Both TBARS and DOPA have a similar trend to the protein content (Figure 3.1.14a) in 
plaque E as they all have a relatively consistent levels across the first five sections of the 
plaque before a significant decrease in concentration of section 6 (Figures 3.1.15a and 
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3.1.15d). The free 7-KC had variable concentration across the length of the plaque, 
showing significant increases (P<0.001) in sections 3 and 5. There was also an increase 
in the total 7-KC concentration in section 3, as well as a significant drop in concentration 
for both of the markers in the post-bifurcation zone (Figure 3.1.15c). AAS and GGS both 
remained at consistent concentrations across all sections of plaque E. AAS gave an 
average concentration of 36.87 ± 3.55 nmoles/g plaque and GSS 15.32 ± 1.51 nmoles/g 
plaque (Figure 3.1.15c). The dityrosine content was below the detectable limit in section 
1 but remained at a consistent concentration throughout the remaining sections of plaque 
E (Figure 3.1.15e). A total of seven markers (protein, cholesterol, α-tocopherol, TBARS, 
free 7-KC, total 7-KC and DOPA) showed a significant decrease in the post-bifurcation 
zone, section 6. But with the exception of 7-KC and total pterin there was not a lot of 
variation between the previous five sections across the length of this plaque. 
  
3.1.6 Correlations between Markers of Individual Plaques 
Correlation statistics were applied to all possible pairs of markers in each plaque, with all 
significant positive and negative correlations displayed in Tables 3.1.6. and 3.1.7. 
Although there was a large amount of variation in marker correlation, highlighting the 
differences between and within the plaques, some correlations occurred twice or more 
among the five plaques (A-E). 
 
Only one correlation occurred in all five plaques, a positive correlation between α-
tocopherol vs. cholesterol which was highly significant in all occasions (Table 3.1.6). 
This correlation was also significant in four of the previously analysed plaques (Table 
3.1.7). The positive correlation between AAS and GGS protein carbonyls was significant 
in four of the five plaques (plaques A, B, C and D). Another two major correlations with 
three out of the five plaques having a positive correlations were between protein vs. 
TBARS, and protein vs. free 7-KC. Many correlations did occur twice with some pairs of 
plaques sharing more than on set of correlations. Plaques A and D both shared two 
negative correlations between protein vs. dityrosine and neopterin vs. dityrosine, the 
negative neopterin and dityrosine correlation was found in two more of the previously 
analysed plaques (Table 3.1.7). Plaques D and E both shared a vast seven positive 
correlations together between neopterin vs. protein, neopterin vs. TBARS, DOPA vs. 
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TBARS, total 7-KC vs. protein, total 7-KC vs. neopterin, total 7-KC vs. TBARS and 
total 7-KC vs. free 7-KC (Table 3.1.7). 
 
Table 3.1.6 Correlation of Inflammatory and Oxidative Markers in Plaques A-E 
Significant correlations were determined based on the average of each section (n=3) 
within plaques A-E using  Statistica's correlation matrices. (+) Indicates a positive 
correlation, (-) indicates a negative correlation. Letter abbreviations in table correspond 
to the plaque assigned letters. Extended table in Appendix. Statistical significance 
represented by P<0.05 * P<0.01 ** P<0.001 *** 
 
 Pro Chol Neop α-toc TBARS DOPA Dityr AAS GGS Free 7-KC 
Chol -A* +C** 
         
Neop +D*** +E* 
-A*** 
+E* 
        
α-toc 
 +A*** 
+B*** 
+C** 
+D** 
+E*** 
-A*        
TBARS 
+B*** 
+D*** 
+E* 
 +D*** 
+E** 
       
DOPA 
-B* 
+D** 
 -A* 
+D* 
 -B*** 
+D** 
+E** 
     
Dityr 
-A* 
-D** 
+E* 
+A*** -A** 
-D** 
+A** -D*** 
+E* 
+E**     
AAS +A** +B** 
-A** 
+C** 
+A*** -A* 
+C** 
+B*** -B***     
GGS 
+E* -A** +A*** -A** 
+B* 
+A* -A* -A* 
+E* 
+A*** 
+B** 
+C* 
+D*** 
  
Free  
7-KC 
+B* 
+D*** 
+E** 
+E* +D***  +D*** +D* -D*** 
+E* 
   
Total 7-
KC 
+D*** 
+E** 
+E* +D*** 
+E** 
 +D*** 
+E* 
+C** 
+D** 
-D***  +E* +D*** 
+E** 
Pro – Protein, Chol – Cholesterol, Neop – Neopterin, α-toc - α-tocopherol, Dityr –
Dityrosine, AAS – AAS protein carbonyl, GGS – GGS protein carbonyl, 7-KC – 7-
ketocholesterol 
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Table 3.1.7 Correlation of Inflammatory and Oxidative Markers in Plaques A-S 
Significant correlations were determined based on the average of each section (n=3) 
within plaques A-S. Plaques A-E were analysed in this study using Statistica's correlation 
matrices Plaques H-M were analysed by Flavall (2008) and plaques N-S by Crone 
(2008). (+) Indicates a positive correlation, (-) indicates a negative correlation. Letter 
abbreviations in table correspond to the plaque assigned letters. Statistical significance 
represented by P<0.05 * P<0.01 ** P<0.001 *** 
 Pro Chol Neop α-toc TBAR DOPA Dityr AAS GGS Free 7-KC 
Chol 
-A* 
+C** 
-K* 
+R* 
         
Neop 
+D*** 
+E* 
+J* 
+L** 
+N*** 
-A*** 
+E* 
        
α-toc 
+N* +A*** 
+B*** 
+C** 
+D** 
+E*** 
+H*** 
+L** 
+P* 
+R*** 
-A* 
+N* 
       
TBARS 
+B*** 
+D*** 
+E* 
+R* 
+M* 
+R** 
+D*** 
+E** 
+M* 
+N* 
+J* 
+R* 
      
DOPA 
-B* 
+D** 
+Q** 
+M* 
-P** 
-A* 
+D* 
-P* -B*** 
+D** 
+E** 
-Q* 
     
Dityr 
-A* 
-D** 
+E* 
+H* 
+Q* 
+A*** 
+I* 
+P* 
-A** 
-D** 
-K* 
-P* 
+A** 
-Q* 
-D*** 
+E* 
+E**     
G C P +L* -K* +L* +I* +N** 
+K* 
+N** 
+O*     
AAS +A** +B** 
-A** 
+C** 
+A*** -A* 
+C** 
+B*** -B***     
GGS 
+E* -A** +A*** -A** 
+B* 
+A* -A* -A* 
+E* 
+A*** 
+B** 
+C* 
+D*** 
  
Free  
7-KC 
+B* 
+D*** 
+E** 
+E* +D***  +D*** +D* -D*** 
+E* 
   
Total 7-
KC 
+D*** 
+E** 
+E* +D*** 
+E** 
 +D*** 
+E* 
+C** 
+D** 
-D***  +E* +D*** 
+E** 
Pro – Protein, Chol – Cholesterol, Neop – Neopterin, α-toc - α-tocopherol, Dityr –
Dityrosine, G C P – General Protein Carbonyls, AAS – AAS protein carbonyl, GGS – 
GGS protein carbonyl, 7-KC – 7-ketocholesterol 
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3.1.7 Combined Plaque Analysis 
Due to a small sample set (N=5) and the complexity of the plaques, correlations within 
the individual plaques (A-E) occurred between almost all the pairs of markers (Table 
3.1.6 and Figure 3.1.16a). Using a higher number of plaque samples it is more likely that 
common factors and correlations will emerge. This research was a continuation from a 
PhD (Firth, 2006) and two masters (Crone, 2008; Flavall, 2008) research which has 
collectively analysed some of the same markers within thirteen plaques. To better 
understand the processes occurring within these plaques the entire eighteen plaques were 
statistically analysed to identify any underlying trends within the inflammatory and 
oxidative markers.  
 
All of the eighteen plaques were in an advanced stage of the disease with stenosis 
between 60-90%. The patients presented with a range of symptoms including stroke, 
transient ischemic attack (very short lived occlusion of artery in brain), and amaurosis 
fugax (temporary loss of vision) (Table 3.1.9, Figure 3.1.16 and Figure 3.1.17). The 
plaques were classified by there difference  in morphological shapes, being either in the 
form of a Y shape where both branches were of similar size, had a smaller secondary side 
branch, or was linear with no side protrusions. Another qualitative characteristic assessed 
during homogenisation was the overall composition of the plaque, this was classified as 
being either calcified, contained an obvious thrombus or did not strongly have either of 
these features (Table 3.1.8). 
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Table 3.1.8 Summary of Clinical and Patient Information in Plaques A-S 
Plaque Total 
Mass (g) 
Morp. Composition Section
N 
Location 
Symptoms 
LC RC LF RF 
A 1.179 Small Neither 9     TIA 
B 0.406 Y Neither 6     Stroke 
C 0.167 Linear Neither 4     Stroke 
D 0.536 Small Calcified 6     Stroke 
E 0.914 Small Neither 6     TIA 
F 0.909 Linear Neither 6     TIA 
G 2.857 Linear Calcified 7     Stroke 
H 1.500 Small Neither 8     TIA 
I 0.763 Small Thrombosis 7     Stroke 
J 1.306 Small Calcified 7     TIA 
K 0.822 Y Thrombosis 6     AF 
L 0.597 Y Calcified 6     Stroke 
M 0.377 Small Thrombosis 6     AF 
N 1.156 Y Calcified 8     Unknown 
O 0.472 Linear Calcified 3     Unknown 
P 0.814 Linear Neither 7     TIA 
Q 1.238 Y Thrombosis 7     Stroke 
R 0.943 Small Thrombosis 8     Asymptom 
S 0.692 Linear Unknown Whole     TIA 
Overall morphology (Morp.): Y – Y shaped, Small – small secondary branch and linear. 
Overall composition (Composition):Thrombosed, calcified or neither. 
Section:  number of sections each plaque was homogenised into. 
Arterial location in plaque: LC – left carotid, RC – right carotid, LF – left femoral, and 
RF – right femoral. 
Patient Symptoms: TIA – transient ischemic attack, AF – amaurosis fugax, Stroke, and 
asymptomatic. 
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3.1.8 Correlations for the Combined Plaque Data 
Combined the eighteen plaques still showed a positive correlation between cholesterol 
and α-tocopherol (Table 3.1.9). α-Tocopherol also positively correlated with protein and 
general protein carbonyls (only analysed in plaques F-S). However α-tocopherol did not 
correlate to either of the specific protein carbonyls AAS and GGS (analysed in plaques 
A-E). 
 
The general protein carbonyls (F-S) positively correlated to protein and neopterin, 
although both specific protein carbonyls AAS and GGS showed only a very high 
statistical correlation to protein (P<0.001), but no correlation to neopterin. AAS and GGS 
both had positive correlations with TBARS, free 7-KC and each other (Table 3.1.8). This 
difference in the correlations of the general protein carbonyls and AAS and GGS protein 
carbonyls may be due to the specificity of the new protein carbonyl assay, or because 
only five plaques (A-E) have been analysed for AAS and GGS. 
 
A significant correlation within the individual plaques was between protein vs. TBARS 
(Table 3.1.6) with three of the five plaques (B, D and E) showing a positive correlation 
did not show a correlation when all the eighteen plaques data was combined, as only one 
other plaque (R) also showed this correlation (Table 3.1.7). Three significant positive 
correlations were observed in the combined plaque analysis that was not seen in any of 
the individual plaque correlations. These were α-tocopherol vs. protein (P<0.001), free 7-
KC vs. AAS protein carbonyl (P<0.05) and free 7-KC vs. GGS protein carbonyl 
(P<0.001). This difference in marker correlations between the individual plaques and the 
combined plaque data further supports the diversity among atherosclerotic plaques. 
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Table 3.1.9 Combined Correlation of Inflammatory and Oxidative Markers 
between Plaques A-S 
Combined plaque analysis was preformed on plaques A-N, P-R. The N column is the 
collated number of plaque sections the correlation analysis was preformed on. For 
neopterin correlations plaques F-I were excluded therefore there are lesser number of 
sections were analysed. For AAS and GGS protein carbonyls correlations only data from 
plaques from A-E (a total of 31 sections) was analysed, and for 7-ketocholesterol 
correlations only data from plaques B-E (a total of 22 sections) was analysed. Protein 
was expressed in mg/g plaque, cholesterol µmole/g plaque and neopterin, α-tocopherol, 
TBARS, DOPA, Dityrosine, AAS and GGS protein carbonyls and 7-ketocholesterol as 
nmole/g plaque. Statistical significance represented by P<0.05 * P<0.01 ** P<0.001 ***  
Markers R value P value N 
(sections)
Combined data analysis 
α-tocopherol vs. Protein 
α-tocopherol vs. Cholesterol 
α-tocopherol vs. Protein carbonyls 
DOPA vs. Protein 
DOPA vs. Dityrosine 
TBARS vs. Neopterin 
Protein carbonyls vs. Protein 
Protein carbonyls vs. Neopterin 
AAS protein carbonyls vs. Protein 
AAS protein carbonyls vs. TBARS 
GGS protein carbonyls vs. Protein 
GGS protein carbonyls vs. TBARS 
GGS protein carbonyls vs. Dityrosine 
GGS protein carbonyls vs. AAS 
Free 7-ketocholesterol vs. Protein 
Free 7-ketocholesterol vs. TBARS 
Free 7-ketocholesterol vs. AAS 
Free 7-ketocholesterol vs. GGS 
Total 7-ketocholesterol vs. Cholesterol 
Total 7-ketocholesterol vs. Free 7-kc 
 
0.4135 
0.2137 
0.2804 
0.2134 
0.2634 
0.2479 
0.3025 
0.3807 
0.8210 
0.6822 
0.6471 
0.7098 
-0.3625 
0.7950 
0.5906 
0.6144 
0.5199 
0.7048 
0.5483 
0.7755 
 
0.0002 
0.0043 
0.0091 
0.0204 
0.0042 
0.0231 
0.0042 
0.0033 
0.0001 
0.0001 
0.0002 
0.0001 
0.0453 
0.0002 
0.0041 
0.0022 
0.0131 
0.0002 
0.0081 
0.0003 
 
*** 
** 
** 
* 
** 
* 
** 
** 
*** 
*** 
*** 
*** 
* 
*** 
** 
** 
* 
*** 
** 
*** 
 
114 
114 
87 
114 
114 
80 
87 
59 
31 
31 
31 
31 
31 
31 
22 
22 
22 
22 
22 
22 
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Figure 3.1.16 Correlation Graphs between Interesting Markers for Combined 
Plaque Data Correlations 
All correlation graphs were analysed by Prism (version 5, GraphPad Software, USA). 
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Figure 3.1.17 Correlation Graphs between Interesting Markers for Combined 
Plaque Data Correlations (2) 
All correlation graphs were analysed by Prism (version 5, GraphPad Software, USA). 
 
3.1.9 Variation in Marker Concentration across the Zones 
To identify if the concentrations of the inflammatory and oxidative markers varied 
significantly across the three zones of the plaque, each plaque data was split into the pre-
bifurcation, bifurcation and post-bifurcation zones and assessed by one-way ANOVA 
and Tukey test. 
 
Protein, even though not significant at a p value of 0.096, had a lower concentration in 
the bifurcation zone (Figure 3.1.18a). The pre-bifurcation zone of cholesterol was on the 
verge of being significantly lower (P=0.0503) than the bifurcation and post-bifurcation 
zones (Figure 3.1.18b). Neopterin’s concentration was the higher in the pre-bifurcation 
zone, although not significantly, than the bifurcation zone (P = 0.078), with α-tocopherol 
exhibiting the opposite trend with its highest concentration in the post-bifurcation zone 
(P=0.22) (Figures 3.1.18c and 3.1.18d). The concentration of DOPA does not vary 
significantly across the three zones of the plaque (Figure 3.1.18e). Where as dityrosine 
had a similar trend to cholesterol, with the pre-bifurcation zone having a significantly 
lower concentration (P<0.05) than the bifurcation and post-bifurcation zones (Figure 
3.1.18f) 
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Figure 3.1.18 Effects of Zoning on the Concentration of the Inflammatory and 
Oxidative Markers within Plaques A-S 
Data from each section from plaques A-S (N=18) were classified into either pre-
bifurcation (Pre-), bifurcation or post-bifurcation (Post-) zones. The variation between 
the concentrations of protein (a), cholesterol (b), neopterin (c), α-tocopherol (d), DOPA 
(e) and dityrosine (f) within each zone was assessed by one way-ANOVA and Tukey’s 
test. Displayed are the means and vertical bars represent the SEM. For the neopterin data 
only plaques A-E and J-R were included (N=13). Significant differences between zones 
are represented by P<0.05 * P<0.01 ** P<0.001 *** 
 
Results 58
Pre- Bifurcation Post-
6
8
10
12
14a)
TB
A
R
S 
(n
m
ol
es
/g
 p
la
qu
e)
Pre- Bifurcation Post-
250
300
350
400b)
Pr
ot
ie
n 
C
ab
on
yl
s (
nm
ol
es
/g
 p
la
qu
e)
Pre- Bifurcation Post-
20
40
60
80
100
120
140
160
**
***
c)
A
A
S 
Pr
ot
ei
n 
C
ar
bo
ny
ls
(n
m
ol
es
/g
 p
la
qu
e)
Pre- Bifurcation Post-
0
10
20
30
40
50
60
70
*
**
d)
G
G
S 
Pr
ot
ei
n 
Ca
rb
on
yl
s
(n
m
ol
es
/g
 p
la
qu
e)
 
Pre- Bifurcation Post-
20
40
60
80
100
120
140
160
*
e)
Fr
ee
 7
-K
C 
(n
m
ol
es
/g
 p
la
qu
e)
Pre- Bifurcation Post-
60
120
180
240
300
360
420
**
f)
To
ta
l 7
-K
C
 (n
m
ol
es
/g
 p
la
qu
e)
 
Figure 3.1.19 Effects of Zoning on the Concentration of the Oxidative Markers 
within Plaques A-S 
Data from each section from plaques A-S (N=18) were classified into either pre-
bifurcation (Pre-), bifurcation or post-bifurcation (Post-) zones. The variation between 
the concentrations of TBARS (a), protein carbonyls (b), AAS protein carbonyl (c), GGS 
protein carbonyl (d), free 7-ketocholesterol (e) and total 7-ketocholesterol (f) within each 
zone was assessed by one way-ANOVA and Tukey’s test. Displayed are the means and 
vertical bars represent the SEM. For the protein carbonyls data only plaques F-R were 
included (N=13), for both the AAS and GGS protein carbonyl data only plaques A-E 
were included (N=5) and for the 7-ketocholesterol data only plaques B-E were included 
(N=4). Significant differences between zones are represented by P<0.05 * P<0.01 ** 
P<0.001 *** 
 
TBARS had a high concentration across the pre-bifurcation and bifurcation zones that 
decreased almost significantly (P=0.056) in the post-bifurcation zone (Figure 3.1.19a). 
All three types of the protein carbonyls showed a similar trend, with a decrease in the 
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concentration between the pre-bifurcation and bifurcation zones. Though only the AAS 
and GGS protein carbonyls had a significant decrease in their concentrations. AAS had a 
P<0.01 and GGS a P<0.05 difference between the pre-bifurcation and bifurcation zones. 
Between the pre-bifurcation and post-bifurcation zones the difference for AAS was 
P<0.001 and GGS was P<0.01 (Figures 3.1.19b, 3.1.19c and 3.1.19d).  The decrease in 
the concentration of free 7-ketocholesterol occurs along the length of the plaque with the 
pre-bifurcation zone containing significantly more than the post-bifurcation zone 
(P<0.05) (Figure3.1.17e). In contrast the total 7-keteocholesterol concentration remains 
constant in the pre-bifurcation and bifurcation zones before dropping significantly in the 
post-bifurcation zone (P<0.01) (Figure 3.1.17f).  
 
The general zoning trend appears to have high concentrations of protein, cholesterol, α-
tocopherol and dityrosine in the post-bifurcation zone of the plaque. With most of the 
oxidation markers (DOPA, TBARS, protein carbonyls, AAS protein carbonyls, GGS 
protein carbonyls, free 7-ketocholesterol and total 7-ketocholesterol) being at their 
highest concentrations in the pre-bifurcation zone and lowest in the post-bifurcation 
zone. In the pre-bifurcation zone where all the oxidation markers (except dityrosine) are 
at their highest levels the only anti-oxidant, α-tocopherol, is at its lowest concentration. 
Yet when all the oxidation markers (except dityrosine) are at their lowest concentrations 
in the post-bifurcation zone α-tocopherol is at its highest level, indicating that in general 
the higher the anti-oxidant level in the plaque the lower the amount of oxidation that is 
occurring. 
 
3.2 Neopterin and 7,8-Dihydroneopterin Concentrations in 
Human Plasma of CHD Patients Undergoing an 
Angioplasty 
 
The inflammation marker neopterin has been found within femoral and carotid 
atherosclerotic plaques (A-S) analysed in our laboratories research, but it has also been 
found to be elevated in patients with cardio heart disease (Ray et al., 2007; Sahin et al., 
2008; Schumacher et al., 1997; Tatzber et al., 1991). By adjusting the previous neopterin 
assay, using a new Phenomenex reverse phase Synergi 4u Hydro-RP 80A, 250 x 4.6 mm 
column and increasing the amount of acidic iodide added, the complete conversion of 
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7,8-dihydroneopterin into the fluoresce neopterin was accomplished which gave the 
accurate amount of total pterin (neopterin plus 7,8-dihydroneopterin) via HPLC. This 
new neopterin assay gave the ability to detect both neopterin and 7,8-dihydroneoptin in 
the plasma of cardio heart disease (CHD) patients. 
 
Our laboratory worked with Dr Catriona Marshall and Dr Dougal McClean from 
Christchurch Hospital’s Department of Cardiology, and obtained a large number of 
plasma samples from CHD patients. These samples came from two different groups of 
patients, one group with acute ST-elevation myocardial infarction (STEMI) (N=24), the 
other group with chronic stable angina (N=11). As a control a group, healthy volunteers 
gave a small blood sample (N=21). 
 
The patients with CHD each had up to eight plasma samples taken while they underwent 
an angioplasty procedure. Some samples were taken before the stent was inserted (pre) 
and some after the stent was in place and the blood flow was restored (post). The sites the 
plasma was taken was from the femoral artery (FA), the aorta (AO pre and post), the 
coronary sinus (CS pre and post), the coronary artery (CA pre and post), and from the 
forearm vein 24 hours after the operation (24hr). Some patients were not able to give a 
sample from every site due to a low blood volume caused by the plaque blockage. The 
healthy volunteers gave just one sample which was taken from the forearm vein. Each 
plasma sample was analysed for neopterin and 7,8-dihydroneopterin, with all assays 
carried out in duplicate. 
 
3.2.1 Plasma Neopterin Levels between Sample Sites. 
 
Across the eight sample sites the plasma was obtained their was no significant difference 
in the concentration of neopterin or 7,8-dihydroneopterin (Figure 3.2.1and Figure 3.2.2). 
Prior to this study it was thought that sites around the heart, closest to the plaque, may 
contain more neopterin than away from the plaque such as the femoral artery site. Within 
this sample size of 35 patients not one showed a significant difference between the 
femoral artery and the other sites, between the pre and post stenting sites, or even 24 
hours after the operation.  
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Figure 3.2.1 Concentrations of Neopterin, 7,8-Dihydroneoptein and Total Pterin in      
Patients with STEMI or Chronic Stable Angina  
Plasma was taken from eight different sites, femoral artery (FA), Aorta (AO pre and post 
stent), coronary sinus (CS pre and post stent), coronary artery (CA pre and post stent) and 
24 hours after operation (24hrs). Graph (a) shows the concentrations from patients 
undergoing an acute ST-elevation myocardial infarction (STEMI) (N=24), and graph (b) 
shows the concentrations from patients with chronic stable angina (N=11).  Points 
represent the mean ± SEM. 
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Figure 3.2.2 Concentrations of Neopterin, 7,8-Dihydroneoptein and Total Pterin in 
CHD Patients 
Plasma data from cardio heart disease (CHD) patients, a combination of both groups 
STEMI and chronic angina patients, was analysed using the neopterin assay on the 
HPLC. The plasma was taken from eight different sites, femoral artery (FA), Aorta (AO 
pre and post stent), coronary sinus (CS pre and post stent), coronary artery (CA pre and 
post stent) and 24 hours after operation (24hrs). Points represent the mean ± SEM. 
 
Figure 3.2.1 shows the separate data of both groups, while figure 3.2.2 contains the 
combined data of the CHD patients. Statistical analysis was carried out on both the 
STEMI group and the chronic angina group. There was no significant difference between 
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the two groups and therefore in the subsequent figures all data was combined into a 
general CHD group.  
The average concentration of neopterin across all sample sites was 14.38 nM, the average 
concentration of 7,8-dihydroneopterin was 55.59 nM (Figure 3.2.2). This means that 
there was almost four times more 7,8-dihydroneopterin than neopterin in the plasma of 
cardio heart disease patients. 
 
3.2.2 Coronary Heart Disease and Healthy Neopterin Concentrations 
The data obtained from the femoral artery of the CHD patients was compared to the data 
from the healthy volunteers. The femoral artery was chosen as it was the only site that 
every patient gave a plasma sample from. The average neopterin concentration from the 
healthy volunteers was 6.83 ± 1.88 nM while the CHD patients average neopterin 
concentration was significantly higher (P<0.01) at 14.38 ± 1.53 nM. (Figure 3.2.3a) The 
difference between the 7,8-dihydroneopterin average concentrations were also highly 
significant (P<0.001) with the average healthy concentration at 17.78 ± 1.66 nM and the 
average CHD 7,8-dihydroneopterin concentration at 55.59 ± 5.19 nM (Figure 3.2.3b). 
Combined together the neopterin and 7,8-dihydroneopterin gave the total pterin 
concentration, this also showed that patients with CHD contained significantly more total 
pterin in their blood stream than the healthy volunteers (Figure 3.2.3c). 
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Figure 3.2.3 Comparison of Neopterin Levels in CHD Patients and Healthy 
Volunteers 
For healthy volunteers (N=22), and CHD patients (N=34) plasma was analysed for 
neopterin (a), 7,8-dihydroneopterin (b) and total pterin (c). Data is presented as box plots 
with median lines and whiskers representing the 5th and 95th percentiles. Statistical 
significances are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***.  
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3.2.3 Time from Onset of Chest Pain in STEMI Group and Neopterin 
Levels 
 
The acute ST-elevation myocardial infarction (STEMI) patient’s plasma samples were 
divided into two sets. They were divided by the time of the onset of the chest pain to the 
first blood sampling at the femoral artery, as either less than 180 minutes (N=11) or 
greater than 180 minutes (N=12). The samples taken less than 180 minutes from the 
onset of pain tended to have lower levels of neopterin (P=0.33), 7,8-dihydroneopterin 
(P=0.091) and total pterin (P=0.100) than the samples taken after 180 minutes. Although 
none of the markers showed a significant difference between the two time groups, 7,8-
dihydroneopterin had the greatest separation between the averages. The average 7,8-
dihydroneopterin concentration for patients who experienced less than 180 minutes of 
pain was 43.040 nM, while the average concentration for patients that had greater than 
180 minutes of pain was 64.837 nM a 33% increase. This indicates that there is a 
possibility that the longer a myocardial infarction remains untreated, the greater the level 
of inflammation occurring. This could lead to a greater amount of 7,8-dihydroneopterin 
being produced. 
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Figure 3.2.4 Comparison of Plasma in Patients with Acute STEMI Divided on Time 
of Onset of Pain.       
For under 180 minutes (N=11), and for over 180 minutes (N=12) plasma was analysed 
for neopterin (a), 7,8-dihydroneopterin (b) and total pterin (c). All samples were taken 
from the femoral artery of the STEMI group of patients. Data is presented as box plots 
with median lines and whiskers representing the 5th and 95th percentiles. Statistical 
significances are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***.  
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3.2.4 Comparison between Neopterin and Age 
Other illnesses and diseases can often increase inflammation throughout the body and in 
turn increase the concentrations of neopterin and 7,8-dihydroneopterin in the plasma. 
Some of these illnesses and diseases include, diabetes, cancers and arthritis (Hamerlinck, 
1999; Hoffmann et al., 2003), and they are often associated with increasing age. 
 
The CHD patients in this study varied in age from 36 to 82 years old, and gave an even 
division of under 65’s (N=17) and over 65’s (N=18). In this group of patients there was 
very little difference in the neopterin and 7,8-dihydroneopterin concentrations between 
the under and over 65’s. This suggests that the over 65 group had no serious underlying 
medical conditions, other than coronary heart disease, that increased their inflammation 
levels above the under 65 group. 
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Figure 3.2.5 Comparison of Plasma from CHD Patients Dependent on Age. 
The plasma was divided by age as under 65 (N=17) and over 65 (N=18), and it was then 
analysed for neopterin (a), 7,8-dihydroneopterin (b) and total pterin (c). All samples were 
taken from the femoral artery of the STEMI group of patients. Data is presented as box 
plots with median lines and whiskers representing the 5th and 95th percentiles. Statistical 
significances are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***.   
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Discussion 
 
A total of 19 advanced atherosclerotic plaques have been fully analysed by our 
laboratory, and each one has had its own unique biochemical composition. During this 
research it has become apparent that no two plaques develop in the same manner with the 
oxidant and antioxidant markers occurring in different concentrations not only between 
individual plaques but also between different sections within the same plaque. This 
variation can be seen in plaques C and E where there is over a 7 fold difference in the 
total 7-ketocholesterol content between the two plaques, with concentrations of 63.84 ± 
4.96 and 454.84 ± 48.64 nmole/g of plaque respectively (Table III). The 7,8-
dihydroneopterin content in plaque D shows how greatly markers can vary throughout 
plaque sections, 7,8-NP is only present in two sections of plaque D but in section 5 its 
concentration is highly elevated at 753.9 ± 68.5 pmole/g of plaque which is 26 times 
more than the amount of neopterin present in the same section (Figure 3.1.11). This 
variation in marker localisation and concentration levels indicates that plaque growth 
may occur under different mechanisms between separate plaques or between different 
sections of the same plaque. 
 
Individual plaque correlations for plaques A-E showed a large amount of both positive 
and negative correlations between many of the markers (Table 3.1.7). Yet when the 
correlations were examined on the combined data a lesser number of correlations became 
significant and some appeared that had not been present in the individual correlations 
(Table 3.1.9).  
 
While trends in the markers across the individual plaques appeared varied, splitting the 
marker concentrations into the three zones clearly showed the majority of the oxidation 
markers to be at their lowest concentrations in the post-bifurcation zone while this is 
where the antioxidant α-tocopherol was at its highest concentration (Figure 3.1.18 and 
Figure 3.1.19). These trends indicate that despite all the differences in the individual 
plaques there are general trends which could apply to most plaques. 
 
Neopterin and 7,8-dihydroneopterin were both found to be significantly elevated in the 
plasma of patients with chronic stable angina and undergoing a myocardial infarction 
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compared to the healthy controls. 7,8-Dihydroneopterin’s levels were on average 4 times 
higher than neopterin levels in the coronary heart disease patients indicating that while 
neopterin is a good marker of inflammation and the severity of atherosclerosis, obviously 
the majority of 7,8-dihydroneopterin is not immediately converted to neopterin and 
therefore both markers need to be measured to obtain a correct value of the inflammation 
in plaques. 
 
4.1 Comparison of the Biochemical Marker Concentrations with 
Published Literature 
 
From the twelve biochemical markers measured in the atherosclerotic plaques (A-S), 
eight have been previously quantified in published literature (Brown et al., 1997; 
Carpenter et al., 1993; Fu et al., 1998; Iuliano et al., 2003; Jachec et al., 2003; Micheletta 
et al., 2004; Nishi et al., 2002; Upston et al., 2002). There is currently no literature on the 
protein carbonyls AAS and GGS being measured within atherosclerotic plaque tissue by 
other laboratories. Even though Adachi et al. (2007) and Sugioka et al. (2010) have both 
detected neopterin in atherosclerotic plaques through immunohistochemical staining they 
did not quantify the concentration of neopterin present. Therefore our laboratory is the 
first to quantify the levels of neopterin and 7,8-dihydroneopterin,  as well as AAS and 
GGS in atherosclerotic plaques. 
 
The average amount of total cholesterol within the plaques (A-S), was 48.41 ± 6.30 
µmole/g of plaque, this is in agreement with Iuliano et al. (2003) and Micheletta et al. 
(2004) who both determined the cholesterol content of carotid plaques to be 40.6 ± 28.7 
µmole/g tissue. The protein concentration in atherosclerotic plaques has been quantified 
at 1.49 ± 0.62 mg/ml of plaque homogenate by Upston et al. (2002). Although lower it is 
still comparable to the average protein concentration for plaque A-S of 2.23 ± 0.35 
mg/ml of plaque homogenate. 
 
α-Tocopherol has been quantified within plaque tissue by several research groups as both 
nmole/g of plaque tissue and as mmole/mol of cholesterol. The average α-tocopherol 
concentration for plaques A-S was 123.28 ± 20.41 nmole/g of plaque, which is similar 
with Carpenter et al. (1993), Iuliano et al. (2003) and Micheletta et al. (2004) who 
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reported α-tocopherol concentrations of 156 ± 118, 85.6 ± 62.1 and 71.3 ± 49.2 nmole/g 
plaque tissue respectively. The α-tocopherol level, expressed as α-tocopherol per mole of 
cholesterol, for plaques A-S was 2.73 ± 0.33 mmole/mol of cholesterol, was within the 
range of values given by Carpenter et al. (1993), Micheletta et al. (2004) and Upston et 
al. (2002) which was between 2.0 and 5.4 mmole/mol of cholesterol. 
 
Nishi et al. (2002) reported a TBARS average concentration of 35.9 ± 3.1 nmole/g of 
plaque tissue which is higher than the average for the plaques A-S of 12.26 ± 3.75 
nmole/g of plaque. TBARS concentration varied dramatically throughout the plaques A-
S with the lowest concentration recorded at 3.46 nmole/g and the highest concentration at 
76.31 nmole/g of plaque. This variation in TBARS concentration within atherosclerotic 
plaques was also detailed in Jachec et al. (2003) who reported a range of 0.23 to 37.36 
µg/g of tissue. Unfortunately the concentrations of plaques A-S can not be directly 
compared to the values given in Jachec et al. (2003) due to the difference in the units of 
measure, but it can be concluded that the highly variable concentrations of TBARS 
between different plaques has been previously quantified. Within plaques A-S the 
average concentrations for DOPA and dityrosine were 14.42 ± 1.67 and 4.44 ± 0.89 
nmole/g of plaque tissue respectively. These values agree with previous DOPA and 
dityrosine concentrations measured in carotid plaques of 14.26 ± 3.8 and 4.75 ± 5.17 
nmole/g of plaque tissue respectively (Fu et al., 1998). As the 7-ketocholesterol assay 
was only introduced with plaque B just four plaques have the concentrations for free and 
total 7-ketocholesterol. Plaque C had the lowest overall concentration of 15.55 nmole/g 
of plaque for free and 63.84 ± 4.96 nmole/g of plaque for total. While plaque E had the 
highest concentration of 108.32 nmole/g of plaque for free and 454.84 ± 48.64 nmole/g 
of plaque for total. The averages for the four plaques for the free 7-ketocholesterol was 
63.68 ± 19.34 nmole/g of plaque was higher than that published by Iuliano et al. (2003) 
and Micheletta et al. (2004) of 35.9 ± 21.5 and 39.7 ± 14.0 nmole/g of tissue 
respectively. However Jachec et al. (2003) showed atherosclerotic plaques to have a free 
7-ketocholesterol concentration range of 14.8 to 577.5 ng/g of tissue. Even though this 
data can not be directly compared to the data from plaques B-E due to the difference in 
the units of measurement value (nmoles/g vs. ng/g) it does show that large variations in 
free 7-ketocholesterol concentrations within plaques has been previously documented. 
Brown et al. (1997) detailed in their paper the 7-ketocholesterol content in two carotid 
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plaques. They found the free 7-ketocholestrol level to be 17 ± 21 nmole/g of plaque, 
which is much lower than our average but similar to the amount found in plaque C. They 
found the concentration of total (free plus esterified) 7-ketocholesterol to be 117 ± 42 
nmole/g of plaque, this agrees with data form plaques B-D. Within human atherosclerotic 
plaques 80-95% of the 7-ketocholesterol of esterified (Brown et al., 1997; Brown & 
Jessup, 2009), in plaques B-D 71% appeared to be esterified. 
 
4.2 Correlations between the Markers across the Atherosclerotic 
Plaques 
 
There was a high degree of variation in the marker concentrations and correlations 
between the individual plaques. This may possibly occur due to the differences in the 
patients from whom the plaques where taken, but also due to variations in the age or 
stage of growth each individual plaque was in. It is presumed that the chemical 
composition of each lesion changes continuously due to variations in the oxidant-
antioxidant balance and the lipid content of the diet. Despite these differences in the 
plaques, significant correlations were seen between many pairs of markers. These 
correlations may provide insight into the interactions and influences the markers have on 
each other. 
 
α-Tocopherol 
α-Tocopherol correlated positively with cholesterol in all five of the plaques and in the 
combined plaque data (Table 3.1.6 and Table 3.1.9). This was the strongest correlation 
between two markers to be seen in all the plaque data. Both α-tocopherol and cholesterol 
are brought into the plaque by LDL. α-Tocopherol is the most prevalent antioxidant in 
LDL with 5-9 in each LDL particle (Pryor., 2000). While LDL is the major carrier of 
cholesterol in macrophage foam cells with atherosclerotic plaques (Brown et al., 1997; 
Kruth et al., 2002). α-Tocopherol also had a very strong positive correlation (p<0.001) 
with protein in the combined data, this was also seen in by Crone (2008) and Flavall 
(2008) in their combined plaque data. Although there were no correlations seen in any of 
the individual plaques A-E, only plaque N (Crone., 2008) has shown a positive 
correlation between these two markers. It is unclear what the connection between α-
tocopherol and protein may be. 
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Protein Oxidation 
In the combined plaque data DOPA, the protein carbonyls AAS and GGS all correlated 
with protein. This could be expected as protein is the major substrate for their oxidation. 
The correlations in the individual plaques between these protein oxidation products, 
including dityrosine, and protein was not seen in all plaques possibly due to their 
specificity. DOPA and dityrosine are formed by oxidation of tyrosine, while AAS and 
GGS protein carbonyls are formed by the metal ion-catalyzed oxidation of proline, 
arginine and lysine residues. Because AAS and GGS are formed by the same process it is 
not surprising that they both positively correlate with each other, in the combined plaque 
data as well as in four of the five individual plaques. DOPA and dityrosine also 
correlated together in the combined data. This has been previously observed by both 
Crone (2008) and Flavall (2008) indicating that overall these two markers appear to be 
formed by the same process within the artery wall. Across all plaques the levels of 
DOPA were consistently higher than those of dityrosine, although not every plaque or 
section contained detectable levels of dityrosine. This difference in the levels of DOPA 
and dityrosine has also been previously documented in Fu et al. (1998) and a reason for 
this may be that dityrosine is formed from the dimerization of two tyrosine phenoxyl 
radicals where the levels are critically dependant on the radical flux and do not increase 
in a linear manner with increasing radical concentrations (Fu et al., 1998). Therefore the 
differing levels of dityrosine per parent tyrosine might indicate that the levels of radical 
flux differ along and between atherosclerotic plaques. 
 
Lipid Peroxidation 
Total 7-ketocholesterol positively correlated with cholesterol in the combined plaque 
data but only plaque E showed a correlation between the two for the individual plaques. 
7-Ketocholesterol is formed when a free radical directly attacks at cholesterols seventh 
carbon. Esterified 7-Ketocholesterol formed from either esterified cholesterol or 
esterified after oxidation makes up 80-95% of the total 7-KC found in plaques (Brown & 
Jessup, 2009) which is most likely why in the combined data only the total 7-
ketocholesterol correlated with the cholesterol and not the free. As they have the same 
method of formation, the free and total 7-ketocholesterol were expected to correlate 
positively with each other. While only free 7-ketocholesterol correlated to TBARS in the 
combined data, total 7-ketocholesterol also show positive correlations with TBARS in 
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the individual plaque data. This correlation may exist as both are lipid oxidation 
products, and Nishi et al. (2002) showed there was a strong correlation between lipid 
peroxidation and the total lipid content within atherosclerotic plaques. TBARS had a 
positive correlation with neopterin in the combined data as well as in two of the 
individual plaques. This correlation may occur as neopterin and TBARS are oxidation 
products and are likely to both be formed at sites of oxidative stress. 
The lipid peroxidation products, free 7-ketocholesterol and TBARS, correlated with AAS 
and GGS protein carbonyls in the combined plaque data. The connection and therefore 
the  correlations between  these lipid peroxidation products and protein oxidation 
products may have occurred as a result of the formation and decomposition of lipid 
peroxides in the presence of redox-active iron to yield aldhydes (Li et al., 2006), or when 
lipid peroxidation takes place the generation of reactive oxygen species in turn oxidises 
nearby proteins (Berlett & Stadtman,  1997) 
 
4.3 Effect of Zoning and Shear Stress on Marker Concentrations in            
Atherosclerotic Plaques. 
 
It has been well established that atherosclerotic plaques often occur in specific areas in 
the arteries, such as branch points and areas of major curvature, where disturbed blood 
flow causes endothelial shear stress (ESS) (Chatzizisis et al., 2007, Gimborne, 1999). 
The level of shear stress differs across the length of the plaque and it is known to disrupt 
the function of endothelial cells. Since the endothelial cells form the barrier between the 
intima and the circulating blood, shear stress possesses the ability to cause LDL to 
accumulate and therefore it can affect the concentrations of cholesterol and α-tocopherol 
across the plaque (Chapman, 2007). The cholesterol content increased in the bifurcation 
and post-bifurcation zones, while α-tocopherol was greatly increased in the post-
bifurcation zone (Figure3.1.18). These trends may be explained by the occurrence of low 
or oscillatory ESS which has been reported to increase the accumulation of lipids 
(Chatzizisis et al., 2007). 
 
The neopterin concentration was at the highest levels in the pre-bifurcation zone, this 
region of the plaque this thought of as the leading edge of the plaque. This is the newest 
area of plaque growth, it has the greater number of activated macrophages with little to 
no gruel. The gruel from carotid plaques has been shown to highly toxic to human 
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macrophages (Li et al., 2006) therefore the macrophages present within the gruel, which 
is predominantly found in the bifurcation and post-bifurcation zones, are most likely to 
be dead. This could explain why the level of neopterin is so low in the bifurcation zone. 
While all five plaques (A-E) where analysed for the presence of 7,8-dihydroneopterin it 
was only detected in a few sections in three of the plaques. It is possible the highly 
oxidative environment within the plaques oxidised the 7,8-dihydroneoptrin to neopterin. 
Therefore there is not enough data at this stage to give a picture of where in the plaque it 
may localise. In plaque C, 7,8-dihydroneopterin was present in relatively equal amounts 
throughout the length of the plaques four sections, plaque C did not have any pre-
bifurcation sections (Figure 3.1.8). In plaque D, 7,8-dihydroneopterin was found in the 
first section of the post-bifurcation zone (Figure 3.1.11) and in plaque E one section from 
the pre-bifurcation and one section from the bifurcation zones contained 7,8-
dihydroneopterin (Figure 3.1.14). This small amount of data from 7,8-dihydroneopterin 
seems to suggest that it is not elevated in the pre-bifurcation zone with a reduced level in 
the bifurcation zone as neopterin is, but a larger data set is needed to show a definite 
trend.  
 
All the plaques analysed were in an advanced stage of atherosclerosis with between 60-
95% stenosis. This stenosis generally occurred in either the bifurcation or post-
bifurcation zones, where the artery is narrowed and the amount of gruel and/or calcium is 
increased. Therefore blood flood in the pre-bifurcation zone would slow down and start 
to re-circulate around as it is unable to flow normally through the stenosed region.  The 
presence of stenosis and the re-circulation of blood may result in a low and oscillating 
shear stress within the pre-bifurcation zone (Deplano & Siouffi, 1999). Low ESS 
promotes the production of reactive oxygen species (ROS) in the intima eventually 
leading to the oxidation of LDL, it also down regulates the intracellular ROS scavengers 
(Chatzizisis et al., 2007). This could explain why the lipid oxidation makers, TBARS and 
7-ketocholesterol, are elevated in the pre-bifurcation zone. The increase of ROS, and the 
decrease of ROS scavengers and α-tocopherol could lead to the significantly high levels 
of the protein carbonyls AAS and GGS in the pre-bifurcation zone. Also the high levels 
of neopterin in the pre-bifurcation zone may influence the concentration of the oxidation 
markers as neopterin is believed promote the oxidative potential of reactive oxygen 
species leading of oxidative stress as well (Adachi et al., 2007; Schroecksnadel et al., 
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2006). The level of DOPA is only slightly higher in the pre-bifurcation zone compared to 
the other two zones, and the dityrosine levels show an opposite trend to all the other 
oxidation markers with its lowest concentration in the pre-bifurcation zone and a 
significant increase in the bifurcation and post-bifurcation zones. The reason for 
dityrosine’s trend is unclear, it may be due to the specificity in which dityrosine is 
formed. Or possibly because dityrosine is not always found in all sections of the plaque, 
many plaques have sections with undetectable levels of dityrosine and this may alter the 
zoning results.  
 
4.4 Concentrations of Neopterin and 7,8-Dihydroneopterin in the 
Plasma of Coronary Heart Disease Patients.  
 
The elevated concentration of neopterin in the plasma of patients suffering from both 
acute (myocardial infarctions) and chronic (stable and unstable angina) coronary heart 
diseases is well documented (Avanzas et al., 2005; Djordjevic et al., 2008; García-
González et al., 2008; Garcia-Moll et al., 2000; Murr et al., 2009; Sahin et al., 2008; 
Schumacher et al., 1997; Sugioka et al., 2010; Tatzber et al., 1991; Videm et al., 2007). 
In this study the levels of neopterin and 7,8-dihydroneopterin in patients with chronic 
stable angina and those who had just suffered an acute ST-elevation myocardial 
infarction (STEMI) were significantly elevated compared to a control group of healthy 
volunteers. There was no significant variation in the concentrations of neopterin or 7,8-
dihydroneopterin between the two patient groups, therefore the amount of inflammation 
appears to be the same regardless of whether the disease was acute or chronic. 
 
Plasma neopterin levels in patients with coronary artery disease have been well studied 
with many publications giving the neopterin levels for these types of patients. But there 
is no published literature showing the levels of both neopterin and 7,8-dihydroneopterin 
together in patients with coronary heart disease or in healthy control subjects. In our 
study the average neopterin concentration in the plasma of patients with coronary heart 
disease (CHD) was 14.38 ± 1.53 nM, this is in agreement with the previously published 
average neopterin values for CHD patients of 17.9 nM (Djordjevic et al., 2008), 10.2 nM 
(García-González et al., 2008), 18.5 nM (Sahin et al., 2008), 13.7 nM (Schumacher et al., 
1997), 15.5 nM (Tatzber et al., 1991)  and 17.4 nM (Videm et al., 2007). The average 
neopterin concentration for healthy volunteers in our study was 6.83 ± 1.88 nM, which is 
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also within the range of neopterin values given for the healthy volunteers published as 
10.9 nM (Djordjevic et al., 2008), 6.98 nM (García-González et al., 2008), 8.7 nM (Sahin 
et al., 2008), 6.8 nM (Schumacher et al., 1997) and 5.0 nM (Tatzber et al., 1991). 
 
The levels of 7,8-dihydroneopterin in patients with coronary heart disease (CHD) were 
previously un-quantified, although it is thought that the ratio of neopterin to 7,8-
dihydroneopterin in venous blood is 1:2 and in arterial blood is 1:3 (Hoffmann et al., 
2003; Murr et al., 2002). The amount of 7,8-dihydroneopterin was 3.87 times greater 
than the neopterin in the CHD patient where the blood was taken from the arteries, and 
2.6 times greater than neopterin in the control group where the blood was taken from the 
forearm vein. So while the concentrations of 7,8-dihydroneopterin were significantly 
elevated in the CHD patients compared to the controls, the levels of both groups are still 
within the expected ratios to neopterin to 7,8-dihydroneopterin. This indicates that even 
though significantly more inflammation is occurring in the CHD patients, the 7,8-
dihydroneopterin that is entering the blood stream away from its site of production in the 
plaque may not be becoming oxidised to neopterin by HOCl. In the plaque samples A-E, 
7,8-dihydroneopterin was only found in three of these plaques and even then it was not 
present in all sections. Plaque C had no detectable levels of neopterin but 7,8-
dihydroneopterin was found in all sections, and in section 5 of plaque D the 7,8-
dihydroneopterin concentration was 26 times greater than the neopterin concentration. 
This 7,8-dihydroneopterin that is found in the plaque samples maybe newly synthesized 
from active macrophages and it might eventually become fully oxidised to neopterin. 
This could explain the extremely high levels of neopterin found within the atherosclerotic 
plaques, with an average concentration of 1202 nM in plaques A-S compared to the 
14.38 nM found in the plasma of CHD patients.  
Patients suffering an acute STEMI were divided into two groups depending on whether 
their first blood sample was taken either less than 180 minutes or greater than 180 
minutes from the onset of pain. There was no significant differences in the neopterin or 
7,8-dihydroneopterin concentrations between the two groups. Although 7,8-
dihydroneopterin had the greatest separation between the averages possibly indicating 
that the longer a myocardial infarction remains untreated the more inflammation that 
could occur. When the CHD patients were divided by age, there was no significant 
difference in the concentration of neopterin or 7,8-dihydroneopterin between the over 65 
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and under 65 age groups. Neopterin levels are known to increase with age, most likely 
due to age related inflammatory diseases (Murr et al., 2002), but that was not seen in this 
group of patients indicating the older patients had no serious underlying medical 
conditions, other than coronary heart disease, that increased their inflammation levels 
above the younger patients 
 
4.5 Summary 
The major finding of this study is that oxidant, anti-oxidant and inflammatory markers 
vary greatly along the length of individual plaques and between whole plaques. While no 
two plaques contained the exact same biochemical composition general trends were 
observed with the combined plaque data. Correlations between markers indicated that 
relationships do occur within the plaque. Zoning within the plaque showed that 
endothelial shear stress caused by blood flow results in a separation between the oxidants 
in the pre-bifurcation zone and α-tocopherol in the post-bifurcation zone. The collection 
of plaque data is still ongoing, with the addition of more data stronger correlations and 
zoning trends may be revealed. This may help to understand the marker composition 
within advanced atherosclerotic plaques better, although variations among plaques will 
always exist due to the differences in biochemistry from the patients in which they were 
taken. 
 
The plasma neopterin and 7,8-dihydroneopterin concentrations were significantly 
elevated in patients with both acute and chronic coronary heart disease compared to 
healthy control volunteers. While neopterin was already well known to be elevated, this 
was the first study that showed 7,8-dihydroneopterin to also be significantly elevated.  
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Appendix 
 
 
Table I. Extended Version of Table 3.1.6 Correlation of Inflammatory and Oxidative 
Markers within Plaques A-E  
Significant correlations were determined based on the average of each section a (n=3) 
within plaques A-E. N is the number of sections within each plaque. Combined plaque 
analysis was performed on plaques A-N, P-R, where N is the collated number of sections 
of the plaques. For neopterin correlations plaques F-I were excluded. For AAS and GGS 
protein carbonyls correlations only data from plaques from A-E was analysed, and for 7-
ketocholesterol correlations only data from plaques B-E was analysed. Protein was 
expressed in mg/g plaque, cholesterol µmole/g plaque and neopterin, α-tocopherol, 
TBARS, DOPA, Dityrosine, AAS and GGS protein carbonyls and 7-ketocholesterol as 
nmole/g plaque. Statistical significance represented by P<0.05 * P<0.01 ** P<0.001 ***  
 
Markers r(Pearson) P value N 
 
Plaque A 
Cholesterol vs. Protein  
Cholesterol vs. Neopterin 
Cholesterol vs. α-tocopherol 
Neopterin vs. α-tocopherol 
Neopterin vs. DOPA 
Dityrosine vs. Protein 
Dityrosine vs. Cholesterol 
Dityrosine vs. Neopterin 
Dityrosine vs. α-tocopherol 
AAS protein carbonyl vs. Protein 
AAS protein carbonyl vs. Cholesterol 
AAS protein carbonyl vs. Neopterin 
AAS protein carbonyl vs. α-tocopherol 
GGS protein carbonyl vs. Cholesterol 
GGS protein carbonyl vs. Neopterin 
GGS protein carbonyl vs. α-tocopherol 
GGS protein carbonyl vs. TBARS 
GGS protein carbonyl vs. DOPA 
GGS protein carbonyl vs. Dityrosine 
 
 
-0.4636 
-0.7070 
0.8489 
-0.4256 
-0.4078 
-0.4213 
0.7177 
-0.5714 
0.4999 
0.5005 
-0.5301 
0.7093 
-0.4328 
-0.5889 
0.7249 
-0.4948 
0.4075 
-0.4478 
-0.4173 
 
 
0.0152 
0.0004 
0.0001 
0.0273 
0.0352 
0.0294 
0.0005 
0.0022 
0.0083 
0.0081 
0.0043 
0.0004 
0.0241 
0.0012 
0.0003 
0.0091 
0.0352 
0.0191 
0.0302 
 
 
* 
*** 
*** 
* 
* 
* 
*** 
** 
** 
** 
** 
*** 
* 
** 
*** 
** 
* 
* 
* 
 
 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
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Table I Continued. Extended Version of Table 3.1.6 Correlation of Inflammatory and 
Oxidative Markers within Plaques A-E  
Markers r(Pearson) P value N 
GGS protein carbonyl vs. AAS 
Plaque B 
Cholesterol vs. α-tocopherol 
Protein vs. TBARS 
Protein vs. DOPA 
Protein vs. AAS protein carbonyl 
Protein vs., Free 7-ketocholesterol 
α-tocopherol vs. GGS protein carbonyl 
TBARS vs. DOPA 
TBARS vs. AAS protein carbonyl 
AAS protein carbonyl vs. DOPA 
AAS protein carbonyl vs. GGS  
 
Plaque C 
Cholesterol vs. Protein 
Cholesterol vs. α-tocopherol 
Cholesterol vs. AAS protein carbonyl 
AAS protein carbonyl vs. α-tocopherol 
AAS protein carbonyl vs. GGS  
DOPA vs. Total 7-ketocholesterol 
 
Plaque D 
Protein vs. Neopterin 
Protein vs. TBARS 
Protein vs. DOPA 
Protein vs. Dityrosine 
Cholesterol vs. α-tocopherol 
Neopterin vs. TBARS 
Neopterin vs. DOPA 
Neopterin vs. Dityrosine 
0.9700 
 
0.8741 
0.8684 
-0.5582 
0.6293 
0.4913 
0.5345 
-0.7600 
0.7770 
-0.7593 
0.6653 
 
 
0.7507 
0.7916 
0.7097 
0.8009 
0.6115 
0.7426 
 
 
0.9386 
0.9839 
0.6744 
-0.7259 
0.6351 
0.9672 
0.4837 
-0.7356 
0.0001 
 
0.0002 
0.0001 
0.0162 
0.0053 
0.0381 
0.0223 
0.0002 
0.0001 
0.0003 
0.0032 
 
 
0.0052 
0.0023 
0.0101 
0.0023 
0.0354 
0.0061 
 
 
0.0001 
0.0002 
0.0022 
0.0013 
0.0051 
0.0002 
0.0423 
0.0011 
*** 
 
*** 
*** 
* 
** 
* 
* 
*** 
*** 
*** 
*** 
 
 
** 
** 
* 
** 
* 
** 
 
 
*** 
*** 
** 
** 
** 
*** 
* 
** 
9 
 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
 
 
4 
4 
4 
4 
4 
4 
 
 
6 
6 
6 
6 
6 
6 
6 
6 
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Table I Continued. Extended Version of Table 3.1.6 Correlation of Inflammatory and 
Oxidative Markers within Plaques A-E  
Markers r(Pearson) P value N 
TBARS vs. DOPA 
TBARS vs. Dityrosine 
AAS protein carbonyl vs. GGS 
Free 7-ketocholesterol vs. Protein 
Free 7-ketocholesterol vs. Neopterin 
Free 7-ketocholesterol vs. TBARS 
Free 7-ketocholesterol vs. DOPA 
Free 7-ketocholesterol vs. Dityrosine 
Total 7-ketocholesterol vs. Protein 
Total 7-ketocholesterol vs. Neopterin 
Total 7-ketocholesterol vs. TBARS 
Total 7-ketocholesterol vs. DOPA 
Total 7-ketocholesterol vs. Dityrosine 
Total 7-ketocholesterol vs. Free 7-kc 
 
Plaque E 
Neopterin vs. Protein 
Neopterin vs. Cholesterol 
Neopterin vs. Total pterin 
Neopterin vs. TBARS 
Total pterin vs. TBARS 
TBARS vs. Protein 
TBARS vs. DOPA 
Cholesterol vs. α-tocopherol 
Dityrosine vs. Protein 
Dityrosine vs. TBARS 
Dityrosine vs. DOPA 
Dityrosine vs. GGS protein carbonyl 
GGS protein carbonyl vs. Protein 
Free 7-ketocholesterol vs. Protein 
0.6625 
-0.7439 
0.9772 
0.9758 
0.9625 
0.9839 
0.5806 
-0.7389 
0.9531 
0.9411 
0.9708 
0.5968 
-0.7583 
0.9609 
 
 
0.5167 
0.4985 
0.4872 
0.6204 
0.5432 
0.5525 
0.7288 
0.7500 
0.5258 
0.5237 
0.6020 
0.5329 
0.5358 
0.6914 
0.0032 
0.0001 
0.0003 
0.0001 
0.0001 
0.0003 
0.0123 
0.0002 
0.0001 
0.0001 
0.0002 
0.0093 
0.0004 
0.0002 
 
 
0.0283 
0.0352 
0.0403 
0.0061 
0.0203 
0.0174 
0.0013 
0.0002 
0.0251 
0.0262 
0.0083 
0.0231 
0.0222 
0.0013 
** 
*** 
*** 
*** 
*** 
*** 
* 
*** 
*** 
*** 
*** 
** 
*** 
*** 
 
 
* 
* 
* 
** 
* 
* 
** 
*** 
* 
* 
** 
* 
* 
** 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
 
 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
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Table I Continued. Extended Version of Table 3.1.6 Correlation of Inflammatory and 
Oxidative Markers within Plaques A-E  
Markers r(Pearson) P value N 
Free 7-ketocholesterol vs. Cholesterol 
Free 7-ketocholesterol vs. DOPA 
Total 7-ketocholesterol vs. Protein 
Total 7-ketocholesterol vs. Cholesterol 
Total 7-ketocholesterol vs. Neopterin 
Total 7-ketocholesterol vs. Total pterin 
Total 7-ketocholesterol vs. TBARS 
Total 7-ketocholesterol vs. GGS 
Total 7-ketocholesterol vs. Free 7-kc 
0.4758 
0.4924 
0.6764 
0.5740 
0.6855 
0.5826 
0.5451 
0.5593 
0.7257 
0.0461 
0.0382 
0.0023 
0.0131 
0.0012 
0.0113 
0.0191 
0.0162 
0.0011 
* 
* 
** 
* 
** 
* 
* 
* 
** 
6 
6 
6 
6 
6 
6 
6 
6 
6 
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Table II. Summary of the Average Overall Concentrations of Protein, Cholesterol, 
Neopterin, Total Pterin, α-Tocopherol and TBARS in Plaques A-S. 
Plaques A-E analysed in this study, F-G in Firth (2006), H-M in Flavall (2008) and N-S in 
Crone (2008). Data represents mean ± SEM of the section averages. ND = Not detected. 
Plaque 
(Lab No) Protein Cholesterol 
Neopterin & 
Total Pterin α-Tocopherol TBARS 
 mg/g plaque µmole/g plaque nmole/g plaque nmole/g plaque nmole/g plaque nmole/g plaque 
A (17) 93.68 ± 3.80 58.99 ± 6.85 1.77 ± 0.13 139.41 ± 13.45 4.75 ± 0.17 
B (19) 136.34 ± 7.09 32.10 ± 2.56 
ND 
ND 86.52 ± 7.78 4.73 ± 0.45 
C (21) 119.93 ± 15.09 34.93 ± 8.49 
ND 
0.01 ± 0.00 157.84 ± 23.46 8.00 ± 0.03 
D (23) 151.1 ± 21.98 52.90 ± 4.39 
0.06 ± 0.01 
0.20 ± 0.06 235.08 ± 26.21 10.99 ± 2.60 
E (24) 86.20 ± 3.63 62.87 ± 3.53 
0.05 ± 0.01 
0.13 ± 0.03 151.67 ± 10.14 3.88 ± 0.25 
F (3) 77.62 ± 4.49 37.15 ± 5.01 0.21 ± 0.01* 32.33 ± 4.96 4.59 ± 0.70 
G (4) 66.71 ± 4.02 84.75 ± 12.10 0.16 ± 0.01* 44.49 ± 2.84 3.39 ± 0.41 
H (5) 70.30 ± 6.19 75.82 ± 8.21 0.09 ± 0.00* 57.04 ± 6.57 7.48 ± 0.77 
I (6) 92.04 ± 5.13 80.89 ± 6.38 0.21 ± 0.01* 37.94 ± 5.72 7.43 ± 1.13 
J (7) 64.26 ± 2.20 57.95 ± 4.47 1.59 ± 0.11 127.09 ± 6.84 4.53 ± 0.85 
K (8) 92.14 ± 3.22 47.42 ± 3.28 1.79 ± 0.15 213.09 ± 6.84 7.13 ± 1.15 
L (9) 94.78 ± 13.10 25.81 ± 2.20 1.26 ± 0.18 60.00 ± 5.54 14.28 ± 1.59 
M (10) 140.33 ± 5.45 29.31 ± 3.95 0.92 ± 0.06 152.27 ± 10.42 15. 49 ± 1.61 
N (11) 69.23 ± 7.06 7.85 ± 0.38 2.34 ± 0.41 21.84 ± 1.66 21.31 ± 4.41 
O (12) 45.16 ± 6.02 6.68 ± 0.69 1.57 ± 0.16 9.64 ± 1.79 76.32 ± 16.49 
P (14) 104.29 ± 6.14 43.39 ± 4.94 2.02 ± 0.15 161.70 ± 16.27 12.31 ± 1.24 
Q (15) 120.47 ± 4.10 64.21 ± 2.34 1.93 ± 0.15 95.40 ± 5.25 12.16 ± 0.30 
R (16) 186.59 ± 22.78 44.86 ± 4.46 2.00 ± 0.29 200.56 ± 25.30 4.20 ± 0.29 
S (17) 91.76 ± 4.04 92.61 ± 0.41 0.72 ± 0.01 360.20 ± 24.74 9.84 ± 0.68 
Overall 
Average 100.23 ± 8.01 51.52 ± 5.64 
1.20 ± 0.22 
0.12 ± 0.03 123.28 ± 20.41 12.26 ± 3.72 
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Table III. Summary of the Average Overall Concentrations of DOPA, Dityrosine, 
AAS and GGS Protein Carbonyls, General Protein Carbonyls, Free 7-
Ketocholesterol and Total 7-Ketocholesterol in Plaques A-S. 
Plaques A-E analysed in this study, F-G in Firth (2006), H-M in Flavall (2008) and N-S in 
Crone (2008). The AAS and GGS protein carbonyl method replaced the old protein 
carbonyl method in plaques A-E. The 7-ketocholesterol assay was only introduced from 
plaque B-E. Data represents mean ± SEM of the section averages. ND = Not detected. 
Plaque DOPA Dityrosine AAS  GGS 
Protein 
Carbonyls 
Free 7-KC 
Total 7-KC 
 nmole/g plaque nmole/g plaque nmole/g plaque nmole/g plaque nmole/g plaque 
nmole/g plaque 
nmole/g plaque 
A (17) 13.15 ± 0.75 2.19 ± 0.70 
59.29 ± 7.02 
25.69 ± 5.24 
  
B (19) 7.99 ± 1.49 7.77 ± 1.59 
109.25 ± 9.48 
15.39 ± 1.32 
 
56.03 ± 9.60 
190.03 ± 26.63 
C (21) 24.69 ± 1.64 6.19 ± 0.76 
28.77 ± 3.02 
3.65 ± 0.37 
 
15.55 ± 2.04 
63.84 ± 4.96 
D (23) 27.29 ± 1.60 2.70 ± 0.37 
99.78 ± 14.24 
42.45 ± 3.24 
 
74.85 ± 22.48 
157.53 ± 39.60 
E (24) 8.86 ± 0.48 3.17 ± 0.32 
36.87 ± 1.84 
15.33 ± 0.81 
 
108.32 ± 9.18 
454.84 ± 48.64 
F (3) 12.79 ± 0.66 0.50 ± 0.10  161.52 ± 25.88  
G (4) 11.58 ± 0.67 4.86 ± 1.21  357.32 ± 19.78  
H (5) 15.66 ± 0.71 0.59 ± 0.14  310.21 ± 32.37  
I (6) 29.13 ± 3.45 11.62 ± 2.92  140.86 ± 13.26  
J (7) 4.93 ± 0.61 0.91 ± 0.15  287.52 ± 25.25  
K (8) 15.50 ± 3.47 8.86 ± 1.54  445.04 ± 50.85  
L (9) 7.59 ± 1.96 ND  276.18 ± 46.51  
M (10) 10.80 ± 0.70 9.19 ± 0.89  389.90 ± 38.25  
N (11) 6.44 ± 0.76 0.05 ± 0.03  266.54 ± 62.89  
O (12) 7.01 ± 0/81 ND  159.63 ± 47.15  
P (14) 25.41 ± 2.04 9.11 ± 2.35  369.50 ± 29.29  
Q (15) 16.22 ± 1.08 9.86 ± 1.21  137.32 ± 30.96  
R (16) 13.86 ± 1.47 2.27 ± 0.61  434.20 ± 35.63  
S (17) 16.24 ± 1.63 3.94 ± 0.12  256.10 ± 56.94  
Overall 
Average 
14.41 ± 1.66 4.44 ± 0.89 
66.79 ± 16.26
20.50 ± 6.50 
287.27 ± 28.93 
63.69 ± 19.35
216.56 ± 
83.81 
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Table IV. Neopterin, 7,8-Dihydroneopterin and Total Pterin Concentrations in 
STEMI Patients.  
Concentrations neopterin and total pterin are in nM ± SEM of duplicates. Concentrations 
of 7,8-dihydroneopterin are in nM, obtained by subtracting the neopterin concentration 
from the total pterin concentration. FA – femoral artery, AO pre – aorta pre stent, CS pre – 
coronary sinus pre stent, CA pre – coronary artery pre stent, CA post – coronary artery 
post stent, CS post – coronary sinus post stent, AO post – aorta post stent, 24 hr – 24 hours 
after the operation. 
 FA AO pre CS pre CA pre CA post CS post AO post 24 hr 
 23.36±0.74 22.70±0.63 20.21±1.14 21.97±0.84 19.78±0.02 17.76±2.94 21.71±1.30 14.08±0.10 
RSE 93.80 65.98 63.44 117.54 116.18 122.37 100.81 97.34 
 117.8±13.2 88.69±7.64 83.66±3.12 139.51±4.1 135.96±4.2 140.13±1.5 122.5±18.9 111.42±0.3 
 16.15±1.56 15.05±0.11 18.86±0.38 19.34±0.09 17.26±1.85  18.11±0.05 18.72±0.18 
AM 112.49 93.37 108.81 104.27 89.09  81.71 101.69 
 128.64±2.3 108.43±1.2 127.67±1.5 123.61±0.9 106.4±11.9  99.83±14.2 120.42±3.5 
 15.25±1.11 14.46±0.48 16.10±0.18 16.08±0.25 15.57±0.06 16.98±1.06 16.03±0.08 17.77±0.09 
WW 36.35 55.33 54.52 45.41 68.90 60.54 42.53 61.77 
 51.60±5.83 69.79±3.94 70.62±2.40 61.50±9.36 84.48±0.07 77.53±0.70 58.56±0.17 79.54±0.15 
 17.45±0.06   15.27±0.36 13.70±0.16    
PMU 46.61   44.95 52.62    
 64.07±3.25   60.22±5.25 66.32±0.53    
 24.75±3.81 24.46±3.40 28.48±0.44 33.72±0.60 16.77±0.40 16.24±0.48 13.16±1.37 16.72±0.37 
OE 57.34 53.00 64.99 69.43 57.87 62.89 60.52 55.36 
 82.09±4.12 77.46±0.92 93.48±2.86 103.16±0.6 74.65±0.26 79.13±0.21 73.68±2.04 72.08±1.73 
 10.62±0.70 10.06±0.54 12.08±0.20 12.85±0.27 12.89±0.88 12.12±1.56 13.99±0.17 15.28±0.32 
EM 82.14 75.95 69.16 56.01 70.13 57.54 67.05 72.21 
 92.77±0.44 86.01±0.20 81.24±0.77 68.86±2.07 83.03±2.69 69.67±0.22 81.05±0.47 87.50±0.49 
 8.37±0.07 8.61±0.17 10.18±1.48 9.02±0.07 8.57±0.25 5.80±1.28 7.96±0.00 12.42±1.16 
AP 74.73 89.23 87.67 90.52 104.63 93.98 90.51 80.79 
 83.10±0.71 97.85±0.92 97.85±0.92 99.55±0.23 113.21±0.1 99.78±0.36 98.48±0.20 93.21±0.07 
 12.74±0.03 14.19±0.30 15.34±0.30 12.79±0.04 14.00±0.76 12.48±0.38 8.07±1.66 13.30±0.42 
RW 66.46 92.82 95.39 95.57 91.41 76.01 94.25 98.04 
 79.18±1.06 107.02±0.5 110.73±1.9 108.37±0.4 105.42±1.5 88.50±3.15 102.32±0.3 111.34±1.1 
 5.19±0.74 5.05±0.25 8.86±0.33 5.87±0.04 8.13±0.08 7.84±0.10 7.78±0.03 9.91±0.37 
GW 64.76 54.02 36.29 67.31 50.58 36.74 54.19  
 69.96±0.08 59.08±0.06 45.15±0.09 73.18±1.27 58.71±1.25 44.58±0.00 61.98±0.87  
 13.07±0.36 11.85±0.23 12.76±0.16   13.93±0.34 11.14±0.83 15.95±0.20 
IG 87.75 83.29 93.19   80.53 94.49 78.12 
 100.82±0.5 95.15±0.11 105.95±0.2   94.47±0.17 105.63±0.5 94.07±0.08 
 20.47±0.48 20.76±0.05 19.39±0.03 21.01±0.48 19.31±0.22 17.22±0.12 17.16±0.17 21.66±0.37 
JC 93.30 95.20 87.69 78.99 93.09 94.77 99.69 127.72 
 113.77±1.9 115.97±1.3 107.09±0.2 100.00±2.4 112.40±0.4 112.00±0.2 116.86±0.5 149.38±0.4 
 13.08±0.11   11.87±0.69 10.21±0.20  12.09±0.31 11.78±0.07 
MS 81.14   84.39 78.22  92.02 83.29 
 94.22±0.39   96.26±1.32 88.43±1.75  104.11±0.2 95.07±0.21 
Key: 
Neopterin 
7,8-Dihydroneopterin 
Total Pterin 
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Table IV Continued. Neopterin, 7,8-Dihydroneopterin and Total Pterin 
Concentrations in STEMI Patients. 
 FA AO pre CS pre CA pre CA post CS post AO post 24 hr 
 16.43±0.06 14.88±0.59 14.47±0.12 14.51±0.04 14.50±0.39 14.51±0.16 14.09±0.00 15.27±0.38 
CD 101.28 101.26 107.93 95.09 108.73 99.05 103.67 121.95 
 117.71±0.7 116.15±0.1 122.41±0.6 109.61±2.4 123.23±0.1 113.56±0.9 117.76±1.2 137.23±0.7 
 7.01±0.19 7.77±0.64 6.21±0.20 5.35±0.09 5.78±0.07 5.85±0.12 5.71±0.12 6.68±0.24 
JE 19.27 15.54 18.86 16.52 16.29 16.33 17.56 15.36 
 26.29±0.69 23.31±0.51 25.07±0.25 21.88±0.01 22.08±0.79 22.18±0.29 23.28±0.21 22.04±0.48 
 6.95±0.29 7.10±0.10 7.53±0.06 8.21±0.20 8.06±0.08 7.09±0.00 7.26±0.06 6.40±0.25 
LH 16.46 17.99 16.22 15.23 14.60 17.73 16.21 11.79 
 23.42±0.12 25.09±0.34 23.75±0.01 23.44±7.61 22.66±0.77 24.82±0.14 23.48±0.51 18.19±0.13 
 3.68±0.48 4.57±0.09 7.03±0.16 4.07±0.29 4.87±0.23 4.68±0.36 4.89±0.48 6.31±0.00 
TW 14.56 14.59 2.79 15.53 11.05 12.21 6.13 15.46 
 18.25±0.12 19.17±0.33 9.82±0.11 19.60±0.29 15.92±0.06 16.89±0.38 11.02±0.27 21.77±0.04 
 7.58±0.04 8.31±0.13  9.00±0.10 7.73±0.80  7.60±0.05  
RT 18.22 31.57  23.47 29.80  28.37  
 25.81±0.10 39.89±1.85  32.47±0.02 37.53±1.02  35.98±0.27  
 19.71±0.55 20.16±1.62 19.20±0.58 19.10±1.31 17.53±1.44 19.34±0.12 17.65±0.73 15.75±0.08 
CS 37.27 50.73 40.66 39.54 44.20 50.79 15.12 50.23 
 56.99±0.19 70.89±0.47 59.87±6.80 58.64±8.74 61.74±0.20 70.13±0.00 32.78±1.71 65.98±0.23 
    9.95±1.06    7.86±0.40 
RS2    42.26    27.92 
    52.21±1.13    35.78±0.21 
 5.98±0.06 6.54±0.14 6.67±0.08 5.08±0.84    5.53±0.30 
MH 26.79 17.74 24.79 22.34    25.65 
 32.78±1.71 24.28±0.36 31.47±0.06 27.42±0.65    31.18±0.54 
 36.42±0.10   32.78±0.68 36.42±0.45   53.70±3.64 
WE 55.05   83.87 86.89   82.38 
 91.47±0.03   116.66±0.1 123.32±2.7   136.09±0.2 
 10.69±1.65  13.18±0.07 10.59±1.37 11.27±0.24  10.47±0.09 13.79±0.22 
MF 26.60  21.42 26.50 23.52  22.69 25.75 
 37.29±0.36  34.61±0.25 37.10±0.07 34.80±1.44  33.17±1.05 39.54±0.05 
 16.57±0.21 9.08±0.38 10.21±0.60 9.83±0.88 8.56±0.42 8.81±0.99 6.92±0.21 7.50±0.07 
DG 23.59 18.36 17.23 4.60 6.99 11.92 22.45 21.62 
 40.17±1.54 27.45±6.77 27.44±0.92 14.44±1.45 15.55±3.16 20.73±6.96 29.37±1.54 29.13±0.76 
 5.79±1.57 7.17±0.14 7.30±0.47 6.44±0.45  6.88±0.28 6.67±0.06  
PB 19.14 21.72 13.08 15.24  20.09 15.07  
 24.94±0.62 28.90±2.67 20.38±0.31 21.68±0.72  26.97±0.32 21.75±2.79  
 6.96±0.28 6.29±0.37 6.19±0.15 6.06±0.19 6.75±0.12 5.86±0.05 6.00±0.18 7.11±0.00 
AS 14.53 17.14 18.08 17.65 24.71 19.51 15.42 7.00 
 21.50±2.71 23.44±0.49 24.28±4.52 23.71±4.15 31.47±1.01 25.37±0.08 21.43±0.76 14.11±1.29 
Key: 
Neopterin 
7,8-Dihydroneopterin 
Total Pterin 
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Table V. Neopterin, 7,8-Dihydroneopterin and Total Pterin Concentrations in Stable 
Chronic Angina Patients.  
Concentrations neopterin and total pterin are in nM ± SEM of duplicates. Concentrations 
of 7,8-dihydroneopterin are in nM, obtained by subtracting the neopterin concentration 
from the total pterin concentration. FA – femoral artery, AO pre – aorta pre stent, CS pre – 
coronary sinus pre stent, CA pre – coronary artery pre stent, CA post – coronary artery 
post stent, CS post – coronary sinus post stent, AO post – aorta post stent, 24 hr – 24 hours 
after the operation. 
 FA AO pre CS pre CA pre CA post CS post AO post 24 hr 
 16.05±0.12 18.79±0.17 17.41±0.14 16.87±0.40 19.94±0.74 17.46±0.08 17.12±0.15  
SM 70.23 46.76 47.18 71.30 63.50 73.60 65.09   
 86.29±0.78 65.55±0.04 64.60±0.58 88.17±0.03 83.45±0.75 91.06±0.64 82.22±2.38  
 19.22±0.22 19.94±0.51 17.61±0.13 18.23±0.08 18.07±0.17 18.90±0.10 19.14±0.72  
AW 67.07 58.73 62.12 68.60 65.78 63.21 79.10   
 86.29±0.77 78.68±0.68 79.74±5.93 86.84±2.19 83.86±2.56 82.11±0.40 98.24±2.04  
 51.31±1.64 47.35±2.50 45.47±1.87 38.16±6.63 40.23±0.21 50.00±1.45 38.27±0.57 45.70±0.42 
PM 79.64 57.65 97.75 49.31 52.41 47.23 50.71 71.17 
 130.9±21.2 105.00±2.0 143.22±9.7 87.48±4.52 92.64±0.34 97.24±0.42 88.99±6.33 116.87±0.1 
 11.80±0.19 11.34±0.08 11.39±0.27 10.42±0.05  9.82±0.05 9.73±0.07 10.13±0.22 
BS 51.38 47.16 47.27 57.67   48.78 55.36 63.15 
 63.18±4.99 58.51±0.23 58.67±6.91 68.10±7.60  58.61±2.83 65.09±6.32 73.28±8.92 
 6.33±1.51 2.11±0.31 3.18±0.20 3.08±0.65 5.54±0.17 2.78±0.01 7.12±1.41 8.37±2.08 
AMZ 31.28 30.51 33.28 59.36 48.07 28.55 50.93 31.37 
 37.61±1.58 32.62±1.99 36.46±0.65 62.45±2.81 53.62±4.56 31.34±0.04 58.06±2.08 39.74±1.81 
 19.35±0.34 18.85±1.22 17.36±1.21 17.44±0.37 20.74±0.66 18.13±0.38 17.91±0.03 17.37±0.07 
MJ 44.29 50.59 45.03 48.27 34.43 36.52 46.57 55.98 
 63.64±0.20 69.44±2.09 62.39±0.20 65.71±0.01 55.17±0.72 54.66±0.02 64.49±0.02 73.36±0.84 
PN 10.34±1.95 10.58±1.47 11.41±0.14 8.24±2.24 11.63±0.24 9.40±2.86 10.46±0.35 14.21±0.10 
 14.02±0.70 14.10±0.07  14.73±0.57 13.88±0.31  15.18±0.08 15.39±0.13 
CT 101.73 87.17   84.86 73.99   57.26 65.11 
 115.76±1.4 101.28±1.4  99.60±0.80 87.87±0.27  72.45±0.08 80.50±0.34 
 14.00±1.02   11.50±0.14 12.07±0.00  13.88±0.00 12.05±0.44 
RG 95.70     69.47 104.02   81.17 83.68 
 109.71±0.7   80.97±0.73 116.10±0.4  95.05±2.26 95.73±0.04 
 9.81±0.28 9.00±0.04 9.31±0.09      
KD 87.70 78.22 74.90           
 97.52±0.81 87.22±1.03 84.22±0.66      
 13.76±0.32 15.42±0.54  15.26±0.45 14.21±0.40  14.15±0.05  
BF 23.53 30.47   32.44 31.78   31.34   
 37.30±0.28 45.89±0.02  47.70±0.09 45.99±0.41  45.49±0.46  
 7.16±0.13 7.36±0.00 6.95±0.05   4.77±1.15 4.48±0.77 6.27±0.06 
DD 23.21 30.42 15.79    20.28 18.69 31.51 
 30.38±0.79 37.78±0.19 22.75±0.32   25.05±0.32 23.18±1.03 37.78±0.19 
Key: 
Neopterin 
7,8-Dihydroneopterin 
Total Pterin 
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Table VI. Neopterin, 7,8-Dihydroneopterin and Total Pterin Concentrations in the 
Control Group of Healthy Volunteers.  
Concentrations neopterin and total pterin are in nM ± SEM of duplicates. Concentrations 
of 7,8-dihydroneopterin are in nM, obtained by subtracting the neopterin concentration 
from the total pterin concentration. All samples were taken from the forearm vein. 
 Neopterin 7,8- Dihydroneopterin Total Pterin 
RP 3.28±0.40 40.67 43.96±0.60 
MH 16.13±0.23 27.44 43.57±0.02 
BD 44.09±0.01 22.38 66.48±0.62 
UF 4.89±0.29 16.98 21.87±0.64 
LX 6.88±0.01 18.46 25.35±0.30 
H 1 5.02±0.03 17.18 22.20±0.47 
H 2 3.09±0.17 21.14 24.24±0.85 
H 3 1.24±0.04 18.10 19.35±0.41 
H 4 1.68±0.31 15.07 16.75±0.30 
H 5 5.76±0.01 16.90 22.67±0.69 
H 6 6.10±0.16 18.06 24.16±0.51 
H 7 5.03±0.01 10.46 15.49±0.46 
H 8 4.42±0.16 5.81 10.24±0.04 
H 9 4.62±1.06 15.19 19.81±7.23 
H 10 5.91±0.67 11.62 17.53±0.20 
H 11 2.61±0.15 20.85 23.47±0.43 
H 12 4.97±0.16 7.30 12.28±0.34 
H 13 5.37±0.71 17.97 23.35±0.73 
H 14 3.99±0.44 19.81 23.81±0.44 
H 15 4.42±0.18 15.11 19.53±0.08 
H 16 6.52±0.02 28.21 34.73±0.80 
H 17 4.10±0.11 6.45 10.55±1.04 
 
 
 
 
